NKTRdate,NKTRnews,NKTRsource11/11/20,DJ Press Release: Nektar Therapeutics Presents New -3-,DJGM11/11/20,DJ Press Release: Nektar Therapeutics Presents New -2-,DJGM11/11/20,DJ Press Release: Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting,DJGM11/11/20,Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN11/09/20,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting for 11-November-2020 4:15 PM ET,FCSTEV11/09/20,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - Abstract #355 for 11-November-2020 5:15 PM ET,FCSTEV11/09/20,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - Abstract 451 for 11-November-2020 5:15 PM ET,FCSTEV11/09/20,DJ Press Release: Nektar Therapeutics to Host -2-,DJGM11/09/20,DJ Press Release: Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting,DJGM11/09/20,Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting,PRN11/06/20,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - Abstract #420 for 11-November-2020 1:30 PM ET,FCSTEV11/06/20,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - Abstract #368 for 11-November-2020 11:15 AM ET,FCSTEV11/05/20,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - BEMPEG - CD122 for 9-November-2020,FCSTEV11/05/20,DJ Press Release: Nektar Therapeutics Reports Third -3-,DJGM11/05/20,DJ Press Release: Nektar Therapeutics Reports Third -2-,DJGM11/05/20,DJ Press Release: Nektar Therapeutics Reports Third Quarter 2020 Financial Results,DJGM11/05/20,Nektar Therapeutics Reports Third Quarter 2020 Financial Results,PRN11/05/20,Nektar Therapeutics to Host Earnings Call,NEWS_ACW11/04/20,"DJ Press Release: New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress",DJGM11/04/20,"New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress",PRN10/29/20,Nektar Therapeutics(NKTR-US) Schedules Business Update Call for 4-November-2020 4:15 PM ET,FCSTEV10/29/20,Nektar Therapeutics(NKTR-US) Schedules American College of Rheumatology Congress - Abstract: 1824 for 9-November-2020 9:00 AM ET,FCSTEV10/29/20,DJ Press Release: Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress,DJGM10/29/20,Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress,PRN10/28/20,Nektar Therapeutics(NKTR-US) Schedules Q3 2020 Earnings Call for 5-November-2020 5:00 PM ET,FCSTEV10/28/20,Nektar Therapeutics(NKTR-US) Schedules Q3 2020 Earnings Release for 5-November-2020 4:15 PM ET,FCSTEV10/28/20,"DJ Press Release: Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets",DJGM10/28/20,"Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets",PRN10/27/20,Nektar Therapeutics(NKTR-US) Schedules Bempegaldesleukin Phase 1B Clinical Study Results Call for 27-October-2020 8:30 AM ET,FCSTEV10/27/20,DJ Press Release: Nektar Therapeutics Announces -2-,DJGM10/27/20,DJ Press Release: Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19,DJGM10/27/20,Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19,PRN08/12/20,DJ Press Release: Vaccibody AS and Nektar -2-,DJGM08/12/20,"DJ Press Release: Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck",DJGM08/12/20,"Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck",PRN08/06/20,Nektar Therapeutics(NKTR-US) Schedules Cambridge Healthtech Institute Immuno-Oncology Virtual Summit for 8-October-2020 9:40 AM ET,FCSTEV08/06/20,DJ Press Release: Nektar Therapeutics Reports Second Quarter 2020 Financial Results,DJGM08/06/20,DJ Press Release: Nektar Therapeutics Reports Second -2-,DJGM08/06/20,Nektar Therapeutics Reports Second Quarter 2020 Financial Results,PRN07/28/20,Nektar Therapeutics(NKTR-US) Schedules Q2 2020 Earnings Call for 6-August-2020 5:00 PM ET,FCSTEV07/28/20,Nektar Therapeutics(NKTR-US) Schedules Q2 2020 Earnings Release for 6-August-2020 4:15 PM ET,FCSTEV07/28/20,"DJ Press Release: Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets",DJGM07/28/20,"Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets",PRN06/04/20,"DJ Press Release: Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)",DJGM06/04/20,"Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)",PRN05/29/20,Nektar Therapeutics(NKTR-US) Schedules EULAR E-Congress - Abstract No - THU0054 for 4-June-2020,FCSTEV05/29/20,Nektar Therapeutics(NKTR-US) Schedules EULAR E-Congress for 5-June-2020 11:00 AM ET,FCSTEV05/29/20,DJ Press Release: Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020),DJGM05/29/20,Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020),PRN05/22/20,DJ Press Release: Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal,DJGM05/22/20,Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal,PRN05/07/20,DJ Press Release: Nektar Therapeutics Reports First -3-,DJGM05/07/20,DJ Press Release: Nektar Therapeutics Reports First -2-,DJGM05/07/20,DJ Press Release: Nektar Therapeutics Reports First Quarter 2020 Financial Results,DJGM05/07/20,Nektar Therapeutics Reports First Quarter 2020 Financial Results,PRN05/04/20,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 17-June-2020 5:00 PM ET,FCSTEV04/28/20,Nektar Therapeutics(NKTR-US) Schedules Q1 2020 Earnings Call for 7-May-2020 5:00 PM ET,FCSTEV04/28/20,Nektar Therapeutics(NKTR-US) Schedules Q1 2020 Earnings Release for 7-May-2020 4:15 PM ET,FCSTEV04/28/20,"DJ Press Release: Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets",DJGM04/28/20,"Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets",PRN03/03/20,Nektar Therapeutics(NKTR-US) Schedules Society of Toxicology Meeting - Leung for 18-March-2020 1:45 PM ET,FCSTEV03/03/20,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Health Care Conference for 3-March-2020 9:20 AM ET,FCSTEV03/02/20,Nektar Therapeutics(NKTR-US) Schedules Society of Toxicology Meeting - Gunther for 18-March-2020 1:45 PM ET,FCSTEV02/28/20,Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference,PRN02/28/20,"Nektar Therapeutics(NKTR-US) Schedules Society of Toxicology Meeting - Leung, S., et al for 18-March-2020 1:45 PM ET",FCSTEV02/28/20,Nektar Therapeutics(NKTR-US) Schedules American Chemical Society National Meeting - NKTR-262: Discovery of a novel TLR 7/8 agonist prodrug  for 24-March-2020 10:10 AM ET,FCSTEV02/27/20,DJ Press Release: Nektar Therapeutics Reports Fourth -3-,DJGM02/27/20,DJ Press Release: Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results,DJGM02/27/20,DJ Press Release: Nektar Therapeutics Reports Fourth -2-,DJGM02/27/20,Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results,PRN02/18/20,Nektar Therapeutics(NKTR-US) Schedules Q4 2019 Earnings Release for 27-February-2020 4:15 PM ET,FCSTEV02/18/20,Nektar Therapeutics(NKTR-US) Schedules Q4 2019 Earnings Call for 27-February-2020 5:00 PM ET,FCSTEV02/18/20,"DJ Press Release: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets",DJGM02/18/20,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets",PRN02/03/20,DJ Press Release: Nektar Therapeutics Announces -2-,DJGM02/03/20,"DJ Press Release: Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications",DJGM02/03/20,"Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications",PRN01/29/20,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsæOn Behalf of Investors of Nektar Therapeuticsæ - NKTR,PMZ01/24/20,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics  - NKTR,PRN01/21/20,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsæOn Behalf of Investors of Nektar Therapeutics - NKTR,PMZ01/14/20,DJ Press Release: Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol,DJGM01/14/20,Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol,PRN01/13/20,"Thinking about buying stock in Bilibili, Microsoft, Nio, Nektar Therapeutics, or NVIDIA?",PRN01/10/20,Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders,BW01/10/20,DJ Press Release: Nektar Therapeutics and -4-,DJGM01/10/20,DJ Press Release: Nektar Therapeutics and -3-,DJGM01/10/20,DJ Press Release: Nektar Therapeutics and -2-,DJGM01/10/20,DJ Press Release: Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab),DJGM01/10/20,DJ Press Release: Nektar Therapeutics and -5-,DJGM01/10/20,Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab),BW01/07/20,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Health Care Conference for 13-January-2020 5:30 PM ET,FCSTEV01/07/20,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Health Care Conference - Q&A Session for 13-January-2020 6:00 PM ET,FCSTEV01/07/20,"DJ Press Release: Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",DJGM01/07/20,"Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/17/19,"DJ Press Release: Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.",DJGM12/17/19,"Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.",PRN12/09/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Abstract 4398 for 9-December-2019 6:00 PM ET,FCSTEV12/09/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Abstract 4459 for 9-December-2019 6:00 PM ET,FCSTEV12/09/19,"DJ Press Release: Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting",DJGM12/09/19,DJ Press Release: Nektar Therapeutics Announces -2-,DJGM12/09/19,"Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting",PRN12/08/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Abstract 2866 for 8-December-2019 6:00 PM ET,FCSTEV12/03/19,DJ Press Release: Nektar Appoints John Northcott as Chief Commercial Officer,DJGM12/03/19,Nektar Appoints John Northcott as Chief Commercial Officer,PRN11/13/19,Nektar Therapeutics(NKTR-US) Schedules The Promise of Interleukin-2 Therapy Meeting for 15-November-2019 10:30 AM ET,FCSTEV11/13/19,Nektar Therapeutics(NKTR-US) Schedules Jefferies London Health Care Conference for 20-November-2019 11:00 AM ET,FCSTEV11/13/19,DJ Press Release: Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference,DJGM11/13/19,Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference,PRN11/12/19,Biotechs Seek Advancements in the Immuno-Oncology Field for Childhood Brain Tumors,PRN11/10/19,DJ Press Release: Nektar Therapeutics Presents Data -2-,DJGM11/10/19,"DJ Press Release: Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology",DJGM11/10/19,"Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology",PRN11/09/19,Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN11/07/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Session: 625 for 8-December-2019 6:00 PM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules PEG Europe Conference - Presentation: NKTR-255 for 21-November-2019 6:15 AM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Poster: NKTR-255 for 8-November-2019 7:00 AM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules American College of Rheumatology Meeting for 10-November-2019 9:00 AM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Session: 652 for 9-December-2019 6:00 PM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules PEG Europe Conference for 19-November-2019 12:30 PM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules The Promise of Interleukin-2 Therapy Meeting for 15-November-2019 10:30 AM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules Melanoma Bridge Conference for 7-December-2019 6:00 AM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Session: 704 for 9-December-2019 6:00 PM ET,FCSTEV11/07/19,Nektar Therapeutics(NKTR-US) Schedules The Promise of Interleukin-2 Therapy Meeting for 15-November-2019 8:00 AM ET,FCSTEV11/06/19,DJ Press Release: Nektar Therapeutics Reports -3-,DJGM11/06/19,DJ Press Release: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019,DJGM11/06/19,DJ Press Release: Nektar Therapeutics Reports -2-,DJGM11/06/19,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019,PRN11/04/19,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting for 10-November-2019 9:00 AM ET,FCSTEV11/01/19,DJ Press Release: Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting,DJGM11/01/19,Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting,PRN10/31/19,Nektar Therapeutics(NKTR-US) Schedules Q3 2019 Earnings Release for 6-November-2019 4:03 PM ET,FCSTEV10/31/19,Nektar Therapeutics(NKTR-US) Schedules Q3 2019 Earnings Call for 6-November-2019 5:00 PM ET,FCSTEV10/30/19,"DJ Press Release: Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets",DJGM10/30/19,"Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets",PRN10/29/19,Clinical Trials in Gene Sequencing Reveal Novel Mutations Aiding in New Treatments for Acute Myeloid Leukemia,PRN10/16/19,"FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ",BW10/16/19,"Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma",PRN10/15/19,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm",BW10/15/19,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsæOn Behalf of Investors of Nektar Therapeutics - NKTR,PMZ10/15/19,"INVESTOR DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ",NEWS_ACW10/10/19,"SHAREHOLDER ALERT:  Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ",PMZ10/09/19,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm",PMZ10/07/19,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P623 for 8-November-2019 7:00 AM ET,FCSTEV10/07/19,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract: O35 for 9-November-2019 5:15 PM ET,FCSTEV10/07/19,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P619 for 8-November-2019 7:00 AM ET,FCSTEV10/07/19,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P387 for 8-November-2019 7:00 AM ET,FCSTEV10/07/19,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P622 for 9-November-2019 7:00 AM ET,FCSTEV10/07/19,Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis,PRN10/04/19,"KESSLER TOPAZ MELTZER & CHECK, LLP - DEADLINE REMINDER FOR NEKTAR THERAPEUTICS INVESTORS",NEWS_ACW10/03/19,Zhang Investor Law Reminds Investors of October 18 Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR,PMZ10/02/19,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm",PMZ10/02/19,Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics,PMZ10/02/19,"INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in ERI, NKTR, and GVA of Filing Deadlines",PMZ10/02/19,Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN10/01/19,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsæOn Behalf of Investors of Nektar Therapeutics - NKTR,PMZ10/01/19,"Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors",PMZ10/01/19,Nektar Announces Key Executive Promotions,PRN09/27/19,"ROSEN, A TOP RANKED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action - NKTR",PMZ09/26/19,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics - NKTR",NEWS_ACW09/26/19,Las Vegas Sands Set to Join S&P 500; Nektar Therapeutics to Join S&P MidCap 400; The Pennant Group to Join S&P SmallCap 600,PRN09/26/19,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PRN09/26/19,Zhang Investor Law Reminds Investors of October 18 Deadline in Securities Class Action Lawsuit AgainstæNektar Therapeutics- NKTR,PMZ09/26/19,Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference,PRN09/25/19,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Sarepta Therapeutics, and Canada Goose and Encourages Investors to Contact the Firm",PMZ09/24/19,"INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in CARB, NKTR, and GVA of Filing Deadlines",PMZ09/24/19,"INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ09/23/19,Nektar Therapeutics(NKTR-US) Schedules CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference - Abstract #A001 for 26-September-2019 12:30 PM ET,FCSTEV09/23/19,Nektar Therapeutics(NKTR-US) Schedules CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference - Abstract #A001 for 26-September-2019 7:00 AM ET,FCSTEV09/23/19,Nektar Therapeutics(NKTR-US) Schedules CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference for 26-September-2019 8:30 AM ET,FCSTEV09/23/19,"Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors",PMZ09/23/19,Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference,PRN09/23/19,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ09/20/19,"Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS)æ& Burford Capital Limited (BRFRF, BRFRY) Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC",PMZ09/20/19,Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics,PMZ09/18/19,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm",PMZ09/17/19,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsæOn Behalf of Investors of Nektar Therapeutics - NKTR,PMZ09/17/19,"Kessler Topaz Meltzer & Check, LLP Reminds Nektar Therapeutics Investors of Important Deadline in Securities Fraud Class Action Lawsuit",PMZ09/12/19,"ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action - NKTR",PMZ09/12/19,NKTR CLASS ACTION ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics,PRN09/11/19,"Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors",PMZ09/10/19,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Canada Goose and Encourages Investors to Contact the Firm",PMZ09/06/19,"KESSLER TOPAZ MELTZER & CHECK, LLP - Reminds Investors of Securities Fraud Class Action Lawsuit Against NEKTAR THERAPEUTICS - NKTR",PMZ09/06/19,"Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS)æ& Burford Capital Limited (BRFRF, BRFRY) Class Action Update - Bronstein, Gewirtz & Grossman, LLC",PMZ09/04/19,"Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ",BW09/04/19,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ09/03/19,"Kessler Topaz Meltzer & Check, LLP:  Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR",PRN08/30/19,"Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Nektar Therapeutics",PMZ08/30/19,"ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR",PMZ08/30/19,"LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm",PRN08/27/19,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Granite Construction, Pluralsight, SAExploration, and Nektar and Encourages Investors to Contact the Firm",PMZ08/26/19,Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics,BW08/23/19,"INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019",PMZ08/22/19,Gainey McKenna & Egleston Announces A ClassæAction Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR),PMZ08/21/19,"IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",BW08/21/19,"NEKTAR THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that aæsecuritiesæclassæactionælawsuitæhasæbeenæfiledæinætheæUnited States District for the Northern District of California against Nektar Therapeutics, Inc.",PMZ08/20/19,"Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm",PRN08/19/19,Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR),BW08/15/19,"Bragar Eagel & Squire, P.C. is Investigating Nektar Therapeutics, Inc. (NASDAQ: NKTR) on Behalf of Stockholders and Encourages Nektar Investors to Contact the Firm",PRN08/10/19,"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",BW08/09/19,Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics Investors,BW08/09/19,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics Investors,BW08/08/19,Nektar Therapeutics(NKTR-US) Schedules CAR-TCR Summit for 11-September-2019 6:18 PM ET,FCSTEV08/08/19,Nektar Therapeutics(NKTR-US) Schedules American Pharmacometrics Conference for 20-October-2019,FCSTEV08/08/19,Nektar Therapeutics(NKTR-US) Schedules Oxford Global Advances In Immuno-Oncology USA Congress for 9-October-2019 3:00 PM ET,FCSTEV08/08/19,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019,PRN08/04/19,Nektar Therapeutics(NKTR-US) Schedules Cambridge Healthtech Institute Immuno Oncology Summit for 5-August-2019,FCSTEV08/01/19,Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo¬ (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma,PRN07/31/19,Nektar Therapeutics(NKTR-US) Schedules Q2 2019 Earnings Release for 8-August-2019 4:16 PM ET,FCSTEV07/31/19,Nektar Therapeutics(NKTR-US) Schedules Q2 2019 Earnings Call for 8-August-2019 5:00 PM ET,FCSTEV07/30/19,"Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets",PRN07/24/19,Nektar Therapeutics(NKTR-US) Schedules International Drug Discovery Science & Technology Congress for 25-July-2019,FCSTEV06/13/19,"First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology",PRN06/13/19,Nektar Therapeutics(NKTR-US) Schedules European Rheumatology Congress for 13-June-2019 8:00 AM ET,FCSTEV06/11/19,Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019),PRN06/01/19,Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting,PRN05/24/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #2623 for 1-June-2019 9:00 AM ET,FCSTEV05/23/19,"Nektar Announces the Launch of Inheris Biopharma, Inc.",PRN05/15/19,Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting,PRN05/08/19,Nektar Therapeutics(NKTR-US) Schedules European Hematology Association Congress - Abstract # PS1208 for 15-June-2019 11:30 AM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Poster 168b Abstract # TPS9601 for 3-June-2019 2:15 PM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Poster 228 Abstract 2584 for 1-June-2019 9:00 AM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules European Hematology Association Congress - Abstract # PS1208 for 15-June-2019 10:30 AM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract # 11010 for 3-June-2019 12:30 PM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Poster #416b Abstract # TPS4595 for 3-June-2019 2:15 PM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules Immuno Oncology Congress for 21-May-2019 11:30 AM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Poster #267 Abstract # 2623 for 1-June-2019 9:00 AM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules Pharmaceutical & Bioscience Society Symposium for 11-June-2019 11:45 AM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules Drug Discovery Nexus Conference for 17-May-2019 9:30 AM ET,FCSTEV05/08/19,Nektar Therapeutics(NKTR-US) Schedules European Congress of Rheumatology Conference - Abstract # OP0195 for 13-June-2019 5:20 AM ET,FCSTEV05/08/19,Nektar Therapeutics Reports Financial Results for the First Quarter of 2019,PRN05/03/19,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 12-June-2019 5:00 PM ET,FCSTEV05/01/19,Nektar Therapeutics(NKTR-US) Schedules Q1 2019 Earnings Call for 8-May-2019 5:00 PM ET,FCSTEV05/01/19,Nektar Therapeutics(NKTR-US) Schedules Q1 2019 Earnings Release for 8-May-2019 4:10 PM ET,FCSTEV05/01/19,"Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets",PRN04/02/19,Nektar Therapeutics(NKTR-US) Schedules William Blair Late-Stage Therapeutics Conference for 4-April-2019,FCSTEV04/02/19,Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019,PRN04/01/19,Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019,PRN03/27/19,Biotechnology Companies Rush to Develop Treatments for Various Illnesses Found Globally,PRN03/07/19,Nektar Therapeutics(NKTR-US) Schedules Cowen & Co. Health Care Conference for 12-March-2019 9:20 AM ET,FCSTEV03/06/19,Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference,PRN03/04/19,Biotechnology Companies see Rising Demand for new Therapies,CNW03/04/19,"BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer",PMZ03/01/19,Nektar Therapeutics(NKTR-US) Schedules ASCO-SITC Clinical Immuno-Oncology Symposium - Abstract #28 for 1-March-2019 4:00 PM ET,FCSTEV03/01/19,"Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting",PRN02/28/19,Nektar Therapeutics(NKTR-US) Schedules Immunotherapy of Cancer Conference - Poster P2.12 for 12-April-2019 8:00 AM ET,FCSTEV02/28/19,Nektar Therapeutics(NKTR-US) Schedules ICI-IO Combinations Summit for 20-March-2019 11:30 AM ET,FCSTEV02/28/19,Nektar Therapeutics(NKTR-US) Schedules PEGS Boston Summit for 11-April-2019 1:50 PM ET,FCSTEV02/28/19,Nektar Therapeutics(NKTR-US) Schedules Immunotherapy of Cancer Conference - Poster P2.12 for 11-April-2019 12:20 PM ET,FCSTEV02/28/19,Nektar Therapeutics(NKTR-US) Schedules Keystone Immunotherapy Cancer Conference for 13-March-2019 11:00 AM ET,FCSTEV02/28/19,Nektar Therapeutics(NKTR-US) Schedules ASCO-SITC Clinical Immuno-Oncology Symposium for 1-March-2019 6:00 PM ET,FCSTEV02/28/19,Nektar Therapeutics(NKTR-US) Schedules CHI Immuno-Oncology Summit for 19-March-2019 12:45 PM ET,FCSTEV02/28/19,Nektar Therapeutics(NKTR-US) Schedules International Molecular Medicine Tri-Conference for 12-March-2019 2:25 PM ET,FCSTEV02/28/19,Nektar Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results,PRN02/27/19,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #3265 for 2-April-2019 8:00 AM ET,FCSTEV02/27/19,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #2256 for 1-April-2019 1:00 PM ET,FCSTEV02/27/19,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #3210 for 2-April-2019 8:00 AM ET,FCSTEV02/27/19,Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019,PRN02/25/19,Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium,PRN02/21/19,Nektar Therapeutics(NKTR-US) Schedules Q4 2018 Earnings Call for 28-February-2019 5:00 PM ET,FCSTEV02/21/19,Nektar Therapeutics(NKTR-US) Schedules Q4 2018 Earnings Release for 28-February-2019 4:10 PM ET,FCSTEV02/21/19,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets",PRN02/15/19,Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium,PRN02/13/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Genitourinary Cancers Symposium for 15-February-2019 5:00 PM ET,FCSTEV02/13/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Genitourinary Cancers Symposium - Abstract #: 388 for 15-February-2019 8:15 PM ET,FCSTEV02/13/19,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Genitourinary Cancers Symposium - Abstract #: 388 for 15-February-2019 3:15 PM ET,FCSTEV02/11/19,Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium,PRN01/30/19,Nektar Therapeutics(NKTR-US) Schedules Immuno-Oncology 360Á Conference for 6-February-2019,FCSTEV01/17/19,Nektar Therapeutics(NKTR-US) Schedules Management Meeting - Jefferies for 18-January-2019,FCSTEV01/03/19,ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics,PRN12/27/18,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Healthcare Conference for 8-January-2019 12:00 PM ET,FCSTEV12/27/18,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Healthcare Conference - Breakout Session for 8-January-2019 12:30 PM ET,FCSTEV12/27/18,"Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/20/18,NKTR DEADLINE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action - NKTR,PMZ12/20/18,"CLASS ACTION UPDATE for DY, NKTR and TX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ12/14/18,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ12/13/18,"CLASS ACTION UPDATE for IGCC, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ12/12/18,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Jianpu, Nektar, Honeywell, and Fitbit and Encourages Investors to Contact the Firm",PMZ12/12/18,"Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit against Nektar Therapeutics, Inc.",BW12/11/18,"Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nektar Therapeutics, Inc.",BW12/11/18,SHAREHOLDER ALERT: COST NKTR FIT RBBN SONS MGI ATUS CMCM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ12/10/18,"Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors",BW12/10/18,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NKTR, GSKY, RBBN (SONS), MDR and TX",PMZ12/10/18,"UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ12/10/18,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm",PMZ12/09/18,SHAREHOLDER ALERT: DY NKTR GSKY ATUS TX BA APHA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ12/07/18,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ12/07/18,"CLASS ACTION UPDATE for IGCC, NKTR, FIT and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ12/07/18,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, TRVN, GOOG, NKTR and RYAAY",PMZ12/06/18,"Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors (NKTR)",BW12/06/18,SHAREHOLDER ALERT: JT TRVN HTHT OZK NKTR FIT GSKY ATUS PPDF MAR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ12/05/18,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HTHT, DY, ALGN, NKTR and SYF",PMZ12/04/18,NKTR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR,PRN12/03/18,SHAREHOLDER ALERT: JT TRVN GOOG CWH OZK NKTR SYF AQUA GSKY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ12/03/18,"INVESTOR NOTICE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ12/02/18,"CLASS ACTION UPDATE for GOOG, OZK, IGCC and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ11/30/18,"SHAREHOLDER ALERT:æ Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -æNKTR",PMZ11/30/18,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm",PMZ11/30/18,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOOG, OZK, NKTR, FIT and TSRO",PMZ11/28/18,"Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics, Inc. Investors",BW11/28/18,"CLASS ACTION UPDATE for NKTR, GSKY and RBBN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ11/27/18,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics, Inc. Investors (NKTR)",BW11/26/18,SHAREHOLDER ALERT: HAS CPB ADNT SFIX GOOG CWH OZK NKTR AQUA RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ11/23/18,"SHAREHOLDER ALERT:æ Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -æNKTR",PMZ11/20/18,"CLASS ACTION UPDATE for JT, NKTR and AQUA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ11/20/18,NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action Seeking Investor Losses - NKTR,BW11/19/18,"Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors",PMZ11/18/18,SHAREHOLDER ALERT: TGTX ABBV MGTI HAS CPB CHGG ADNT GOOG NKTR SYF RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ11/16/18,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -æNKTR",PMZ11/14/18,Nektar Therapeutics(NKTR-US) Schedules Jefferies Health Care Conference for 14-November-2018 5:00 AM ET,FCSTEV11/14/18,"Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs",PRN11/14/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Publication #2952 for 2-December-2018 9:00 PM ET,FCSTEV11/12/18,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, Nektar, and Honeywell and Encourages Investors to Contact the Firm",PMZ11/12/18,SHAREHOLDER ALERT: APOG COCP ABBV COST HTHT SFIX CWH OZK NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ11/11/18,"CLASS ACTION UPDATE for APOG, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ11/10/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P424 for 10-November-2018 8:00 AM ET,FCSTEV11/10/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P348 for 10-November-2018 8:00 AM ET,FCSTEV11/10/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P368 for 10-November-2018 8:00 AM ET,FCSTEV11/10/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P364 for 10-November-2018 8:00 AM ET,FCSTEV11/10/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P418 for 10-November-2018 8:00 AM ET,FCSTEV11/10/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P557 for 10-November-2018 8:00 AM ET,FCSTEV11/10/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P419 for 10-November-2018 8:00 AM ET,FCSTEV11/09/18,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P364 for 10-November-2018,FCSTEV11/09/18,Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Misled Shareholders According to Class Action,BW11/09/18,Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN11/09/18,"Kessler Topaz Meltzer & Check, LLP:  Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR",PRN11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P418 for 9-November-2018 8:00 AM ET,FCSTEV11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P364 for 9-November-2018 8:00 AM ET,FCSTEV11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P422 for 9-November-2018 8:00 AM ET,FCSTEV11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P424 for 9-November-2018 8:00 AM ET,FCSTEV11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P419 for 9-November-2018 8:00 AM ET,FCSTEV11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P368 for 9-November-2018 8:00 AM ET,FCSTEV11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P557 for 9-November-2018 8:00 AM ET,FCSTEV11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P378 for 9-November-2018 8:00 AM ET,FCSTEV11/09/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P348 for 9-November-2018 8:00 AM ET,FCSTEV11/08/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P419 for 9-November-2018,FCSTEV11/08/18,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COCP, SFIX, CWH, HON, NKTR and SYF",PMZ11/08/18,"Kessler Topaz Meltzer & Check, LLP - Reminds Investors of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics",BW11/07/18,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018,PRN11/06/18,"Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Nektar Therapeutics",PMZ11/06/18,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRVN, HON, OZK and NKTR",PMZ11/06/18,NKTR LOSS ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR,PMZ11/06/18,"New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers",PRN11/06/18,Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting,PRN11/05/18,"INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ11/05/18,SHAREHOLDER ALERT: PVG USAT COCP JT GOOG OZK NKTR FIT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ11/04/18,"CLASS ACTION UPDATE for HON, DY, NKTR and FIT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ11/04/18,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ10/31/18,Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR),PMZ10/31/18,"CLASS ACTION UPDATE for TGTX, HAS and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ10/31/18,SOFTHALE NV annonce un nouveau membre de son conseil d'administration,PRNE10/31/18,SOFTHALE NV gibt neues Vorstandsmitglied bekannt,PRNE10/30/18,EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR,BW10/30/18,"Pomerantz Law Firm Announces the Filing of a Class Action against Nektar Therapeutics, Inc. and Certain Officers - NKTR",PMZ10/30/18,Nektar Therapeutics(NKTR-US) Schedules Q3 2018 Earnings Call for 7-November-2018 5:00 PM ET,FCSTEV10/30/18,Nektar Therapeutics(NKTR-US) Schedules Q3 2018 Earnings Release for 7-November-2018 4:10 PM ET,FCSTEV10/30/18,"Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets",PRN10/23/18,Nektar Therapeutics(NKTR-US) Schedules TraceLink Futurelink Conference for 6-November-2018,FCSTEV10/12/18,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P348 for 10-November-2018 9:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P424 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P378 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P422 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P368 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P419 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P364 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P418 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract: #O4 for 9-November-2018 5:05 PM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P348 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P557 for 10-November-2018 8:00 AM ET,FCSTEV10/05/18,Nektar Therapeutics(NKTR-US) Schedules American Pharmacometrics Conference for 6-October-2018,FCSTEV10/03/18,Nektar Therapeutics (NKTR) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws,PRN10/02/18,Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN10/01/18,Nektar Therapeutics Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Karin Eastham,PRN09/26/18,Nektar Therapeutics(NKTR-US) Schedules SMI Immuno Oncology Conference for 26-September-2018 6:00 AM ET,FCSTEV09/24/18,BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer,PMZ08/31/18,"Market Trends Toward New Normal in Caesars Entertainment, Nektar Therapeutics, Boston Scientific, Apollo Commercial Real Estate Finance, Kellogg, and Foot Locker - Emerging Consolidated Expectations, Analyst Ratings",PMZ08/16/18,Nektar Therapeutics(NKTR-US) Schedules Morgan Stanley Global Health Care Conference for 12-September-2018 8:45 AM ET,FCSTEV08/08/18,Nektar Therapeutics(NKTR-US) Schedules European Society for Medical Oncology Meeting - Poster #446TiP for 22-October-2018 6:45 AM ET,FCSTEV08/08/18,Nektar Therapeutics(NKTR-US) Schedules American Chemical Society Meeting for 20-August-2018 1:35 PM ET,FCSTEV08/08/18,Nektar Therapeutics(NKTR-US) Schedules European Society for Medical Oncology Meeting - Poster #362TiP for 22-October-2018 6:45 AM ET,FCSTEV08/08/18,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2018,PRN08/01/18,Nektar Therapeutics(NKTR-US) Schedules Q2 2018 Earnings Release for 8-August-2018 4:10 PM ET,FCSTEV08/01/18,Nektar Therapeutics(NKTR-US) Schedules Q2 2018 Earnings Call for 8-August-2018 5:00 PM ET,FCSTEV08/01/18,"Nektar to Announce Financial Results for the Second Quarter 2018 on Wednesday, August 8, 2018, After Close of U.S.-Based Financial Markets",PRN07/31/18,Specialty Oncology Drugs One of the Top Markets Generating Most Growth,PRN07/30/18,Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA,PRN07/26/18,"Investor Expectations to Drive Momentum within Fidelity Southern, Nektar Therapeutics, CSG Systems International, Ellington Financial, NBT, and Paylocity Holding - Discovering Underlying Factors of Influence",PMZ06/26/18,IsoPlexis Announces Research Collaboration with Nektar Therapeutics,PRN06/14/18,"New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting",PRN06/13/18,Nektar Therapeutics(NKTR-US) Schedules William Blair Growth Stock Conference for 13-June-2018 9:40 AM ET,FCSTEV06/05/18,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 6-June-2018 3:00 PM ET,FCSTEV06/05/18,Nektar to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York,PRN06/04/18,"BioXcel Therapeutics and Nektar Therapeutics Present Preclinical Pancreatic Cancer Data for BXCL701, NKTR-214 and Anti-PD1 Combination Therapy at ASCO 2018 Annual Meeting",PMZ06/02/18,"Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018",PRN05/31/18,"Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy",PRN05/30/18,Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration,PRN05/18/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract: #3006 for 2-June-2018 6:00 PM ET,FCSTEV05/18/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #2567 for 4-June-2018 9:00 AM ET,FCSTEV05/18/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract # 3006 for 2-June-2018 6:00 PM ET,FCSTEV05/17/18,BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting,PMZ05/16/18,Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting,PRN05/10/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #TPS3115 for 4-June-2018 9:00 AM ET,FCSTEV05/10/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #TPS1111 for 2-June-2018 9:00 AM ET,FCSTEV05/10/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #2567 for 4-June-2018 9:00 AM ET,FCSTEV05/10/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #5582 for 4-June-2018 2:15 PM ET,FCSTEV05/10/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #3006 for 2-June-2018 4:00 PM ET,FCSTEV05/10/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #3085 for 4-June-2018 9:00 AM ET,FCSTEV05/10/18,Nektar Therapeutics Reports Financial Results for the First Quarter of 2018,PRN05/08/18,"Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus",PRN05/03/18,Nektar Therapeutics(NKTR-US) Schedules Q1 2018 Earnings Call for 10-May-2018 5:00 PM ET,FCSTEV05/03/18,Nektar Therapeutics(NKTR-US) Schedules Q1 2018 Earnings Release for 10-May-2018 4:10 PM ET,FCSTEV05/03/18,"Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets",PRN05/02/18,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 26-June-2018 2:00 PM ET,FCSTEV05/01/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - NKTR-214 for 2-June-2018 6:00 PM ET,FCSTEV04/30/18,Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting,PRN04/24/18,"New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors",PRN04/18/18,"Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and Novavax",PRN04/15/18,Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018,PRN04/11/18,Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors,PRN04/10/18,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Health Care Conference for 8-May-2018 8:40 AM ET,FCSTEV04/03/18,Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb,PRN04/03/18,Nektar Therapeutics(NKTR-US) Schedules William Blair & Company Cancer Immunotherapy Conference - Panel for 4-April-2018 11:35 AM ET,FCSTEV03/09/18,"Take-Two Interactive Software, SVB Financial and Nektar Pharmaceuticals Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600",PRN03/07/18,Nektar Therapeutics(NKTR-US) Schedules Cowen & Co. Health Care Conference for 14-March-2018 8:00 AM ET,FCSTEV03/07/18,Nektar to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference in Boston,PRN03/06/18,Nektar Therapeutics(NKTR-US) Schedules Advances in Immuno-Oncology Congress for 24-May-2018 12:40 PM ET,FCSTEV03/06/18,Nektar Therapeutics(NKTR-US) Schedules American Academy of Pain Medicine Meeting for 27-April-2018 9:00 PM ET,FCSTEV03/02/18,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract - 3755 for 17-April-2018 9:00 AM ET,FCSTEV03/02/18,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract - 2755 for 16-April-2018 2:00 PM ET,FCSTEV03/02/18,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract - 123 for 15-April-2018 2:00 PM ET,FCSTEV03/02/18,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract - 3566 for 17-April-2018 9:00 AM ET,FCSTEV03/01/18,Nektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results,PRN03/01/18,Nektar Therapeutics to Host Earnings Call,NEWS_ACW02/21/18,Nektar Therapeutics(NKTR-US) Schedules Q4 2017 Earnings Call for 1-March-2018 5:00 PM ET,FCSTEV02/21/18,Nektar Therapeutics(NKTR-US) Schedules Q4 2017 Earnings Release for 1-March-2018 4:10 PM ET,FCSTEV02/21/18,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets",PRN02/15/18,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting for 14-April-2018,FCSTEV02/15/18,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #3755 for 2-June-2018 7:45 PM ET,FCSTEV02/14/18,Nektar Therapeutics(NKTR-US) Schedules NKTR-214 Plus Opdivo Update Call for 14-February-2018 8:00 AM ET,FCSTEV02/14/18,"Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar's CD122-biased Agonist, NKTR-214",BW01/03/18,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference for 9-January-2018 2:00 PM ET,FCSTEV01/03/18,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference - Q&A Session for 9-January-2018 2:30 PM ET,FCSTEV01/03/18,"Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/20/17,Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance,BW11/27/17,Nektar Therapeutics(NKTR-US) Schedules Piper Jaffray Health Care Conference for 28-November-2017 5:10 PM ET,FCSTEV11/27/17,Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City,PRN11/22/17,Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline,PRN11/12/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting for 12-November-2017 6:15 AM ET,FCSTEV11/11/17,"First Data for NKTR-214 in Combination with OPDIVO¬ (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017",PRN11/11/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting for 11-November-2017 5:00 PM ET,FCSTEV11/11/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P140 for 11-November-2017 12:30 PM ET,FCSTEV11/11/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P434 for 11-November-2017 12:30 PM ET,FCSTEV11/11/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P332 for 11-November-2017 12:30 PM ET,FCSTEV11/11/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P274 for 11-November-2017 12:30 PM ET,FCSTEV11/10/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P275 for 10-November-2017 12:30 PM ET,FCSTEV11/10/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P77 for 10-November-2017 12:30 PM ET,FCSTEV11/10/17,Nektar Therapeutics(NKTR-US) Schedules Jefferies London Health Care Conference for 15-November-2017 5:00 AM ET,FCSTEV11/10/17,Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference,PRN11/07/17,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017,PRN11/07/17,Nektar Therapeutics(NKTR-US) Schedules American College of Rheumatology Meeting - Abstract 2715 for 7-November-2017 12:00 PM ET,FCSTEV11/07/17,New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting,PRN11/07/17,"Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting",PRN11/01/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting for 11-November-2017 6:15 PM ET,FCSTEV11/01/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P434 for 1-November-2017 12:30 PM ET,FCSTEV10/31/17,Nektar Therapeutics(NKTR-US) Schedules Q3 2017 Earnings Call for 7-November-2017 5:00 PM ET,FCSTEV10/31/17,Nektar Therapeutics(NKTR-US) Schedules Q3 2017 Earnings Release for 7-November-2017 4:10 PM ET,FCSTEV10/31/17,"Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.-Based Financial Markets",PRN09/21/17,Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member,PRN09/21/17,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #PIVOT-02 for 11-November-2017 3:30 PM ET,FCSTEV09/20/17,Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting,PRN09/12/17,"Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ¬ (atezolizumab) or KEYTRUDA¬ (pembrolizumab)",PRN09/09/17,Nektar Therapeutics(NKTR-US) Schedules European Society for Medical Oncology Congress for 9-September-2017 7:15 AM ET,FCSTEV09/06/17,"Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek¬",PRN09/06/17,Nektar Therapeutics(NKTR-US) Schedules Morgan Stanley Global Healthcare Conference for 12-September-2017 12:55 PM ET,FCSTEV09/06/17,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City",PRN08/30/17,"Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek¬",PRN08/08/17,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017,PRN08/08/17,Investor Network: Nektar Therapeutics to Host Earnings Call,NEWS_ACW08/02/17,Nektar Therapeutics(NKTR-US) Schedules Q2 2017 Earnings Call for 8-August-2017 5:00 PM ET,FCSTEV08/02/17,Nektar Therapeutics(NKTR-US) Schedules Q2 2017 Earnings Release for 8-August-2017 4:10 PM ET,FCSTEV08/02/17,"Nektar to Announce Financial Results for the Second Quarter of 2017 on Tuesday, August 8, 2017, After Close of U.S.-Based Financial Markets",PRN07/24/17,"Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy",PRN07/18/17,Nektar Therapeutics(NKTR-US) Schedules NKTR-181 Human Abuse Potential Study Results Call for 18-July-2017 8:45 AM ET,FCSTEV07/18/17,"Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain",PRN07/10/17,"Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London",PRN06/13/17,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 14-June-2017,FCSTEV06/06/17,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Health Care Conference for 7-June-2017 9:30 AM ET,FCSTEV06/06/17,Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City,PRN06/05/17,"Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting",PRN05/22/17,"New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds",PRN05/18/17,Nektar Therapeutics Announces Data Presentations at ASCO 2017,PRN05/15/17,Nektar Therapeutics(NKTR-US) Schedules UBS Global Health Care Conference for 22-May-2017 1:30 PM ET,FCSTEV05/15/17,Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York,PRN05/09/17,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract TPS1120 for 4-June-2017 9:00 AM ET,FCSTEV05/09/17,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract 2545 for 5-June-2017 9:00 AM ET,FCSTEV05/09/17,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract# e14040 for 4-June-2017,FCSTEV05/09/17,Nektar Therapeutics Reports Financial Results for the First Quarter of 2017,PRN05/09/17,Investor Network: Nektar Therapeutics to Host Earnings Call,NEWS_ACW05/03/17,"Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program",PRN05/02/17,Nektar Therapeutics(NKTR-US) Schedules Q1 2017 Earnings Release for 9-May-2017 4:10 PM ET,FCSTEV05/02/17,"Nektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets",PRN04/20/17,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract e14040 for 3-June-2017 7:00 PM ET,FCSTEV04/20/17,Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting,PRN04/10/17,Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology,NEWS_ACW04/04/17,Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting,PRN03/27/17,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1603 for 3-April-2017 8:00 AM ET,FCSTEV03/27/17,"Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders",PRN03/21/17,Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News,NEWS_ACW03/20/17,Nektar Therapeutics(NKTR-US) Schedules NKTR-181 Phase 3 Study Results Call for 20-March-2017 8:45 AM ET,FCSTEV03/20/17,NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain,PRN03/14/17,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 2671 for 3-April-2017 1:00 PM ET,FCSTEV03/14/17,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1603 for 3-April-2017 8:00 AM ET,FCSTEV03/14/17,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1604 for 3-April-2017 8:00 AM ET,FCSTEV03/14/17,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1617 for 3-April-2017 8:00 AM ET,FCSTEV03/14/17,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1598 for 3-April-2017 8:00 AM ET,FCSTEV03/07/17,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Global Health Care Conference for 7-March-2017 11:20 AM ET,FCSTEV03/02/17,Nektar to Webcast Presentation at Cowen and Company's 37th Annual Health Care Conference in Boston,PRN03/01/17,Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting,PRN03/01/17,Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results,PRN02/22/17,Nektar Therapeutics(NKTR-US) Schedules Q4 2016 Earnings Call for 1-March-2017 5:00 PM ET,FCSTEV02/22/17,Nektar Therapeutics(NKTR-US) Schedules Q4 2016 Earnings Release for 1-March-2017 4:10 PM ET,FCSTEV02/22/17,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets",PRN02/18/17,Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium,PRN01/25/17,Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma,NEWS_ACW01/05/17,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference for 10-January-2017 5:00 PM ET,FCSTEV01/05/17,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference - Q&A Session for 10-January-2017 5:30 PM ET,FCSTEV01/05/17,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/11/16,Nektar Therapeutics(NKTR-US) Schedules BMO Capital Markets Prescriptions for Success Healthcare Conference. for 14-December-2016,FCSTEV11/18/16,Nektar Therapeutics(NKTR-US) Schedules RBC Capital Markets' Healthcare Investor Day for 15-December-2016,FCSTEV11/14/16,Nektar Therapeutics(NKTR-US) Schedules Jefferies London Health Care Conference for 16-November-2016 8:20 AM ET,FCSTEV11/14/16,Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London,PRN11/09/16,Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting,PRN11/04/16,Nektar Therapeutics(NKTR-US) Schedules ROTH Capital Partners Innovations in Oncology Corporate Access Day for 17-November-2016,FCSTEV11/03/16,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Sy for 30-November-2016 2:30 AM ET,FCSTEV11/03/16,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016,PRN10/28/16,Nektar Therapeutics(NKTR-US) Schedules Investor and Analyst Meeting for 9-November-2016 2:30 PM ET,FCSTEV10/28/16,Nektar to Hold Investor & Analyst Event at 2016 Society for Immunotherapy of Cancer Annual Meeting,PRN10/28/16,Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for Immunotherapy of Cancer Annual Meeting,PRN10/27/16,Nektar Therapeutics(NKTR-US) Schedules Q3 2016 Earnings Call for 3-November-2016 5:00 PM ET,FCSTEV10/27/16,Nektar Therapeutics(NKTR-US) Schedules Q3 2016 Earnings Release for 3-November-2016 4:10 PM ET,FCSTEV10/27/16,"Nektar to Announce Financial Results for the Third Quarter 2016 on Thursday, November 3, 2016, After Close of U.S.-Based Financial Markets",PRN10/18/16,Nektar Therapeutics Prices Public Offering of Shares of Common Stock,PRN10/18/16,Technologie von Aerogen reduziert Klinikeinlieferungen aus der Notaufnahme um 32 Prozent1,BW10/18/16,La technologie Aerogen r_duit de 32æ% les admissions en services d'urgence1,BW10/17/16,Nektar Therapeutics Announces Public Offering of Shares of Common Stock,PRN09/27/16,Nektar Therapeutics(NKTR-US) Schedules Nektar Therapeutics and Bristol-Myers Squibb New Clinical Collaboration Call for 27-September-2016 9:00 AM ET,FCSTEV09/27/16,Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb,PRN09/27/16,Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214,BW08/03/16,Nektar Therapeutics(NKTR-US) Schedules European Society for Medical Oncology Congress - Abstract #3048 for 9-October-2016 2:00 PM ET,FCSTEV08/03/16,Nektar Therapeutics(NKTR-US) Schedules CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference - Abstract#311 for 26-September-2016 5:15 PM ET,FCSTEV08/03/16,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016,PRN08/03/16,"Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma",PRN07/27/16,Nektar Therapeutics(NKTR-US) Schedules Q2 2016 Earnings Call for 3-August-2016 5:00 PM ET,FCSTEV07/27/16,Nektar Therapeutics(NKTR-US) Schedules Q2 2016 Earnings Release for 3-August-2016 4:15 PM ET,FCSTEV07/27/16,"Nektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets",PRN06/06/16,Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity,PRN06/06/16,Nektar Therapeutics(NKTR-US) Schedules Roth Health Care Day for 22-June-2016,FCSTEV06/03/16,Nektar Therapeutics(NKTR-US) Schedules Jefferies Health Care Conference for 8-June-2016 11:30 AM ET,FCSTEV06/02/16,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City",PRN06/02/16,Nektar Therapeutics Announces Executive Management Promotions,PRN06/01/16,"Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD» (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases",PRN05/19/16,"DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit Against NantKwest, Inc. And Reminds Investors With Losses To Contact The Firm",NEWS_ACW05/19/16,"DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nantkwest, Inc. (NK) and Lead Plaintiff Deadline: May 23, 2016",NEWS_ACW05/17/16,"IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against NantKwest, Inc. And Encourages Investors With Losses To Contact The Firm",NEWS_ACW05/11/16,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Nantkwest, Inc. (NK) and Lead Plaintiff Deadline: May 23, 2016",NEWS_ACW05/03/16,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting for 24-May-2016,FCSTEV05/03/16,Nektar Therapeutics Reports Financial Results for the First Quarter of 2016,PRN05/03/16,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 23-June-2016,FCSTEV04/29/16,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK",NEWS_ACW04/28/16,Nektar Therapeutics(NKTR-US) Schedules Q1 2016 Earnings Call for 3-May-2016 4:30 PM ET,FCSTEV04/28/16,Nektar Therapeutics(NKTR-US) Schedules Q1 2016 Earnings Release for 3-May-2016 After Market Hours ET,FCSTEV04/28/16,"Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets",PRN04/25/16,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Health Care Conference for 5-May-2016 8:40 AM ET,FCSTEV04/22/16,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK",NEWS_ACW04/18/16,Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration,PRN04/06/16,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 - NK",NEWS_ACW04/01/16,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK",NEWS_ACW03/03/16,"Nektar Therapeutics to Present at Cowen and Company's 36th Annual Health Care Conference in Boston, MA",PRN03/02/16,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 558 for 17-April-2016 2:00 PM ET,FCSTEV03/01/16,Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results,PRN02/26/16,Nektar Therapeutics(NKTR-US) Schedules Q4 2015 Earnings Call for 1-March-2016 5:00 PM ET,FCSTEV02/26/16,Nektar Therapeutics(NKTR-US) Schedules Q4 2015 Earnings Release for 1-March-2016 After Market Hours ET,FCSTEV02/26/16,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2015 on Tuesday, March 1, 2016, After Close of U.S.-Based Financial Markets",PRN02/25/16,Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings,PRN02/19/16,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Health Care Conference for 9-March-2016 8:40 AM ET,FCSTEV02/01/16,"Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research",PRN01/25/16,"Technical Recap on Biotechnology Stocks -- Nektar Therapeutics, Novavax, Celgene, and Opko Health",NEWS_ACW01/07/16,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference - Q&A Session for 12-January-2016 2:30 PM ET,FCSTEV01/06/16,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference for 12-January-2016 2:00 PM ET,FCSTEV01/06/16,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/24/15,"Factors Moving Markets - Featured Research on NantKwest, KEYW Holding, NOODLES & CO, and CAI International",NEWS_ACW12/21/15,Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age,PRN12/10/15,"A Change in Tides - Complementary Research on Nektar, California Resources, Zynga and Finisar",NEWS_ACW12/09/15,Nektar Therapeutics(NKTR-US) Schedules ROTH Capital Partners Immuno-Oncology Corporate Access Day for 16-December-2015,FCSTTS12/08/15,Nektar Therapeutics(NKTR-US) Schedules Oppenheimer Health Care Conference for 9-December-2015 1:00 PM ET,FCSTTS12/08/15,Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York,PRN12/08/15,"Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine",PRN11/30/15,"Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule",PRN11/17/15,Nektar Therapeutics(NKTR-US) Schedules Jefferies Autumn Global Health Care Conference for 19-November-2015 11:40 AM ET,FCSTTS11/17/15,Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London,PRN11/05/15,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015,PRN10/29/15,Nektar Therapeutics(NKTR-US) Schedules Q3 2015 Earnings Release for 5-November-2015 After Market Hours ET,FCSTTS10/29/15,Nektar Therapeutics(NKTR-US) Schedules Q3 2015 Earnings Call for 5-November-2015 5:00 PM ET,FCSTTS10/29/15,"Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets",PRN10/08/15,Nektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day,PRN10/07/15,Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies,PRN10/06/15,Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020,PRN10/01/15,Nektar to Host Research & Development Day for Analysts and Investors on October 8th,PRN09/21/15,Nektar Therapeutics(NKTR-US) Schedules Ladenburg Thalmann Health Care Conference for 29-September-2015 3:00 PM ET,FCSTTS09/21/15,"Nektar Presents Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models",PRN09/01/15,Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG¬ (naloxegol) Tablets in Major European Market,PRN08/10/15,"New Webinar on Leveraging Private Social Networking Technology to Maintain Clinical Trial Oversight, Hosted by Xtalks",INW08/07/15,Nektar Therapeutics(NKTR-US) Schedules AACR Inaugural International Cancer Immunotherapy Conference for 18-September-2015 4:30 PM ET,FCSTTS08/05/15,Nektar Therapeutics(NKTR-US) Schedules R&D Day for 8-October-2015 12:30 PM ET,FCSTEV08/05/15,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015,PRN07/31/15,"Biotechnology Stocks on our Scanner -- Agenus, RXi Pharma, Nektar Therapeutics, Genetic Technologies, and Agios Pharma",PRN07/29/15,Nektar Therapeutics(NKTR-US) Schedules Q2 2015 Earnings Call for 5-August-2015 5:00 PM ET,FCSTTS07/29/15,Nektar Therapeutics(NKTR-US) Schedules Q2 2015 Earnings Release for 5-August-2015 After Market Hours ET,FCSTTS07/29/15,"Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets",PRN07/16/15,Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A,PRN06/02/15,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference - Q & A Session for 2-June-2015 9:00 AM ET,FCSTTS06/02/15,"Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine",PRN05/28/15,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 2-June-2015 8:30 AM ET,FCSTTS05/28/15,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2015 Global Healthcare Conference in New York City",PRN05/07/15,"Financial Results Galore: Complementary Research on Accuracy Inc., Teradyne, Nektar, Century Aluminum and Newpark Resources",PRN05/04/15,"Critical Alerts For American Airlines, Nektar Therapeutics, Ocwen Financial, Skyworks Solutions and Chevron Released By InvestorsObserver",PRN05/02/15,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 16-June-2015,FCSTTS04/30/15,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract # 1001 for 1-June-2015 4:12 PM ET,FCSTTS04/30/15,Nektar Therapeutics Reports Financial Results for the First Quarter of 2015,PRN04/23/15,Nektar Therapeutics(NKTR-US) Schedules Q1 2015 Earnings Release for 30-April-2015 After Market Hours ET,FCSTTS04/23/15,Nektar Therapeutics(NKTR-US) Schedules Q1 2015 Earnings Call for 30-April-2015 5:00 PM ET,FCSTTS04/23/15,"Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets",PRN04/16/15,"Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A",PRN04/15/15,"Equities Updates on Pharma Industry -- Eli Lilly, Sanofi, AstraZeneca, Nektar Therapeutics, and BioDelivery Sciences Intl.",PRN04/13/15,Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference,PRN04/02/15,Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca,PRN03/31/15,Nektar Therapeutics(NKTR-US) Schedules Needham & Company Health Care Conference for 15-April-2015 8:00 AM ET,FCSTTS03/31/15,MOVANTIK» (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US,PRN03/19/15,AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US,PRN03/18/15,Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics,PRN03/17/15,Nektar Therapeutics(NKTR-US) Schedules NKTR-102 Phase 3 Study Results Call for 17-March-2015 4:45 PM ET,FCSTTS03/17/15,Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control in Patients with Advanced Breast Cancer in Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08),PRN03/10/15,"Technical Snapshot on Pharma Stocks -- Pfizer, Zogenix, Sanofi, Nektar Therapeutics, and IGI Laboratories",PRN02/25/15,Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain,PRN02/24/15,Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results,PRN02/17/15,Nektar Therapeutics(NKTR-US) Schedules Q4 2014 Earnings Release for 24-February-2015 After Market Hours ET,FCSTTS02/17/15,Nektar Therapeutics(NKTR-US) Schedules Q4 2014 Earnings Call for 24-February-2015 5:00 PM ET,FCSTTS02/17/15,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets",PRN02/11/15,"Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A",PRN01/13/15,"Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics",PRN01/08/15,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Health Care Conference - Q&A Breakout Session for 13-January-2015 2:30 PM ET,FCSTTS01/06/15,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Health Care Conference for 13-January-2015 2:00 PM ET,FCSTTS01/06/15,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/15/14,"Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis",PRN12/11/14,Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer,PRN12/09/14,MOVENTIG¬ Approved In The European Union For Opioid-Induced Constipation,PRN12/01/14,"Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A",PRN11/24/14,FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation,PRN11/20/14,Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model,PRN11/06/14,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014,PRN11/03/14,"Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings",PRN10/30/14,Nektar Therapeutics(NKTR-US) Schedules Q3 2014 Earnings Call for 6-November-2014 5:00 PM ET,FCSTTS10/30/14,Nektar Therapeutics(NKTR-US) Schedules Q3 2014 Earnings Release for 6-November-2014 After Market Hours ET,FCSTTS10/30/14,"Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets",PRN10/09/14,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 19-November-2014,FCSTTS10/08/14,Nektar Therapeutics(NKTR-US) Schedules Brean Capital Life Sciences Summit for 24-November-2014,FCSTTS09/26/14,Nektar Therapeutics Announces MOVENTIG¬ (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation,PRN09/24/14,"Active Equities to Watch in Pharma Industry - Pfizer, BioDelivery Sciences Intl., Repros Therapeutics, Catalent, and Nektar Therapeutics",PRN09/19/14,"Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting",PRN09/16/14,FDA Approves MOVANTIK» (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain,PRN08/21/14,"Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients",PRN08/12/14,"Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics",PRN07/31/14,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014,PRN07/22/14,Nektar Therapeutics(NKTR-US) Schedules Q2 2014 Earnings Call for 31-July-2014 5:00 PM ET,FCSTTS07/22/14,Nektar Therapeutics(NKTR-US) Schedules Q2 2014 Earnings Release for 31-July-2014 After Market Hours ET,FCSTTS07/22/14,"Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets",PRN07/07/14,"Technical Pulse on Pharma Stocks -- Research on Pfizer, Hospira, Endo Intl., and Nektar Therapeutics",PRN07/04/14,"Appointments, Acquisitions, Study Results, and Technical Updates - Analyst Notes on Alere, AMRI, Anika Therapeutics, Nektar and Sangamo",PRN06/19/14,Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients,PRN06/18/14,Nektar Therapeutics(NKTR-US) Schedules Piper Jaffray Catalyst Symposium for 8-July-2014,FCSTTS06/12/14,US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK,PRN06/11/14,Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists,PRN06/01/14,"Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting",PRN05/31/14,Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin¬-Refractory High-Grade Glioma Presented at 50th ASCO Meeting,PRN05/19/14,"Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer",PRN05/16/14,Nektar Therapeutics To Present at the UBS 2014 Global Healthcare Conference in New York City,PRN05/07/14,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract Number: 3082 for 1-June-2014 9:00 AM ET,FCSTTS05/07/14,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract Number: 2096 for 31-May-2014 2:15 PM ET,FCSTTS05/07/14,Nektar Therapeutics Reports Financial Results for the First Quarter of 2014,PRN05/06/14,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 25-June-2014,FCSTTS05/01/14,Nektar Therapeutics(NKTR-US) Schedules Q1 2014 Earnings Call for 7-May-2014 5:00 PM ET,FCSTTS05/01/14,Nektar Therapeutics(NKTR-US) Schedules Q1 2014 Earnings Release for 7-May-2014 After Market Hours ET,FCSTTS05/01/14,"Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday, May 7, 2014, After Close of U.S.-Based Financial Markets",PRN05/01/14,Nektar Therapeutics(NKTR-US) Schedules UBS Global Healthcare Conference for 20-May-2014 2:30 PM ET,FCSTTS04/09/14,Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR,PRN03/04/14,Nektar Therapeutics(NKTR-US) Schedules ROTH Capital Partners Conference for 10-March-2014 2:30 PM ET,FCSTTS02/26/14,Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results,PRN02/19/14,Nektar Therapeutics(NKTR-US) Schedules Q4 2013 Earnings Call for 26-February-2014 5:00 PM ET,FCSTTS02/19/14,Nektar Therapeutics(NKTR-US) Schedules Q4 2013 Earnings Release for 26-February-2014 After Market Hours ET,FCSTTS02/19/14,"Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets",PRN01/22/14,Nektar Therapeutics Prices Public Offering of Common Stock,PRN01/21/14,"Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock",PRN01/18/14,Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium,PRN01/16/14,"Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories",PRN01/14/14,Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer,PRN01/14/14,"First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain",PRN01/08/14,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Healthcare Conference for 14-January-2014 1:00 PM ET,FCSTTS01/08/14,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/25/13,"Addition to Indices, and Stock Price Movements - Research Report on ACADIA Pharmaceuticals, InterMune, Tandem Diabetes Care, Nektar Therapeutics and Greatbatch",PRN12/17/13,"AAAResearchReports.com Pre-Market Technical Analysis: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories",PRN11/28/13,"New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar",PRN11/20/13,"Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar",PRN11/19/13,"Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc.",PRN11/19/13,New Drug Application For Naloxegol Accepted By United States Food And Drug Administration,PRN11/13/13,"Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A",PRN11/12/13,"Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn",PRN11/07/13,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013,PRN10/30/13,Nektar Therapeutics(NKTR-US) Schedules Q3 2013 Earnings Call for 7-November-2013 5:00 PM ET,FCSTEV10/30/13,Nektar Therapeutics(NKTR-US) Schedules Q3 2013 Earnings Release for 7-November-2013 After Market Hours ET,FCSTEV10/30/13,"Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets",PRN10/28/13,"Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc.",PRN10/24/13,Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC),PRN10/16/13,"Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar",PRN10/08/13,Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day,PRN10/07/13,"Regulatory Approvals, Public Offerings and Clinical Trial Results - Research Report on Theravance, Synageva, Nektar, Clovis Oncology, and ImmunoGen",PRN10/03/13,Nektar Therapeutics(NKTR-US) Schedules R&D Day for 8-October-2013 11:30 AM ET,FCSTEV10/02/13,Nektar to Host Investor and Analyst R&D Day in New York City,PRN10/02/13,"Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus",PRN09/30/13,Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol,PRN09/26/13,Nektar Therapeutics(NKTR-US) Schedules Phase 2 NKTR-181 Study Results Call for 26-September-2013 4:30 PM ET,FCSTEV09/26/13,Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee,PRN08/15/13,"Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and Financial Results - Research Report on Alnylam, Infinity, Nektar, Sequenom, and Merrimack",PRN08/12/13,"Wall Street Fundamentals Releases New In-Depth Stock Reports on DNDN, GERN, NKTR and NPSP",NEWS_ACW08/08/13,Nektar Therapeutics(NKTR-US) Schedules European Cancer Congress Conference for 30-September-2013 8:00 AM ET,FCSTEV08/08/13,Nektar Therapeutics(NKTR-US) Schedules American Chemical Society Meeting for 8-September-2013 7:00 PM ET,FCSTEV08/08/13,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013,PRN08/01/13,Nektar Therapeutics(NKTR-US) Schedules Q2 2013 Earnings Call for 8-August-2013 5:00 PM ET,FCSTEV08/01/13,Nektar Therapeutics(NKTR-US) Schedules Q2 2013 Earnings Release for 8-August-2013 After Market Hours ET,FCSTEV08/01/13,"Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets",PRN07/30/13,Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer,PRN06/19/13,Nektar Therapeutics(NKTR-US) Schedules NKTR-181 Study Results Call for 19-June-2013 1:00 PM ET,FCSTEV06/19/13,"Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence",PRN06/03/13,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Annual Meeting - Abstract # 3060 for 3-June-2013 9:00 AM ET,FCSTEV06/03/13,"Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting",PRN06/01/13,Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting,PRN05/31/13,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 4-June-2013 9:00 AM ET,FCSTEV05/30/13,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City",PRN05/21/13,Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013,BW05/16/13,Nektar Therapeutics(NKTR-US) Schedules UBS Global Healthcare Conference for 21-May-2013 10:00 AM ET,FCSTEV05/16/13,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City",PRN05/10/13,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Annual Meeting - Abstract Number: 1087 for 1-June-2013 2:15 PM ET,FCSTEV05/09/13,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Annual Meeting - Abstract Number: 3060 for 1-June-2013 9:00 AM ET,FCSTEV05/09/13,Nektar Therapeutics Reports Financial Results for the First Quarter of 2013,PRN05/02/13,Nektar Therapeutics(NKTR-US) Schedules Q1 2013 Earnings Release for 9-May-2013 After Market Hours ET,FCSTEV05/02/13,Nektar Therapeutics(NKTR-US) Schedules Q1 2013 Earnings Call for 9-May-2013 5:00 PM ET,FCSTEV05/02/13,"Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets",PRN04/29/13,Technical Stock Breakout Watch: Nektar Therapeutics (NKTR),NEWS_ACW04/17/13,"Critical Alerts For Intel, Delta, Southern Copper, Lam Research, and Nektar Therapeutics Released By InvestorsObserver",PRN04/16/13,Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia,PRN04/07/13,"Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013",PRN03/19/13,New Programs Designed to Speed up Approval Process a Key Factor in Biotech Industry's Growth in 2012,INW03/08/13,"Pushing Pipelines Forward for Long-Term Success - Research Report on Vertex, Santarus, Arena Pharmaceuticals, Seattle Genetics and Nektar Therapeutics",PRN03/05/13,Nektar Therapeutics(NKTR-US) Schedules ROTH Capital Partners Growth Stock Conference for 19-March-2013 3:30 PM ET,FCSTEV03/05/13,Nektar Therapeutics(NKTR-US) Schedules American Pain Society Scientific Meeting for 9-May-2013 9:30 AM ET,FCSTEV03/04/13,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #2475 for 9-April-2013 8:00 AM ET,FCSTEV03/04/13,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #482 for 7-April-2013 1:00 PM ET,FCSTEV03/02/13,Nektar Therapeutics(NKTR-US) Schedules Cowen & Company Healthcare Conference for 5-March-2013 8:00 AM ET,FCSTEV03/01/13,Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston,PRN02/28/13,Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results,PRN02/26/13,AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation,PRN02/13/13,Nektar Therapeutics(NKTR-US) Schedules Q4 2012 Earnings Call for 28-February-2013 5:00 PM ET,FCSTEV02/13/13,Nektar Therapeutics(NKTR-US) Schedules Q4 2012 Earnings Release for 28-February-2013 After Market Hours ET,FCSTEV02/13/13,"Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets",PRN02/07/13,Number of FDA Drug Approvals Reach a 15-Year High in 2012,INW02/05/13,Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC),PRN01/23/13,"The Real Story Behind AMBS, ARNA, NKTR and URS",INW01/16/13,Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013,INW01/10/13,"Our Pros Knew HMSY, NKTR, TTM and HSP Would Be Top Gainers on Wednesday ",INW01/10/13,"The Real Story Behind NUVA, NKTR, HOLX and VOLC ",INW01/04/13,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/20/12,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Healthcare Conference for 9-January-2013 11:30 AM ET,FCSTEV11/15/12,"Research Reports on Top Stocks: Verizon, Nokia, CYS Investments, Prospect Capital, Huntington Bancshares, and Nektar Therapeutics",PRN11/13/12,"Free Research Reports on ARRY, CECO, GILD and NKTR Issued by the Bedford Report ",INW11/12/12,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 14-November-2012 6:20 AM ET,FCSTEV11/12/12,AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation,PRN11/12/12,Nektar Therapeutics(NKTR-US) Schedules Naloxegol Pivotal Phase III Trial Results Call for 12-November-2012 8:15 AM ET,FCSTEV11/11/12,Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol,PRN11/07/12,Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer,PRN11/06/12,Nektar Therapeutics(NKTR-US) Schedules Q3 2012 Earnings Release for 13-November-2012 After Market Hours ET,FCSTEV11/06/12,"Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets",PRN10/15/12,"Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society for Neuroscience",PRN10/01/12,GreeneStone Muskoka Once Again Featured on Intervention Canada,BW09/18/12,"NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study",PRN09/13/12,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 19-September-2012 10:30 AM ET,FCSTEV09/13/12,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City",PRN08/09/12,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012,PRN08/07/12,Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma,PRN08/02/12,Nektar Therapeutics(NKTR-US) Schedules Q2 2012 Earnings Call for 9-August-2012 5:00 PM ET,FCSTEV08/02/12,Nektar Therapeutics(NKTR-US) Schedules Q2 2012 Earnings Release for 9-August-2012 After Market Hours ET,FCSTEV08/02/12,"Nektar to Announce Financial Results for the Second Quarter of 2012 On Thursday, August 9, 2012, After Close of U.S.-Based Financial Markets",PRN07/24/12,"Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain",PRN07/10/12,Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017,PRN06/07/12,"Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain",PRN05/30/12,Nektar Therapeutics(NKTR-US) Schedules Jefferies & Co Health Care Conference for 5-June-2012 11:30 AM ET,FCSTEV05/30/12,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York,PRN05/24/12,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology (ASCO) Meeting - Abstract: #5048/18H for 3-June-2012 9:00 AM ET,FCSTEV05/24/12,Nektar Therapeutics(NKTR-US) Schedules American Society of Oncology (ASCO) Meeting - Abstract # TPS1140/36A for 2-June-2012 9:00 AM ET,FCSTEV05/18/12,Fitch Affirms RPI Finance Trust's Ratings at 'BBB-',BW05/02/12,Nektar Therapeutics Reports Financial Results for the First Quarter of 2012,PRN04/26/12,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Health Care Conference for 7-May-2012 4:50 PM ET,FCSTEV04/25/12,Nektar Therapeutics(NKTR-US) Schedules Q1 2012 Earnings Call for 2-May-2012 5:00 PM ET,FCSTEV04/25/12,Nektar Therapeutics(NKTR-US) Schedules Q1 2012 Earnings Release for 2-May-2012 After Market Hours ET,FCSTEV04/25/12,"Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets",PRN04/10/12,Nektar Therapeutics(NKTR-US) Schedules Investor and Analyst R&D Day for 16-April-2012 12:00 PM ET,FCSTEV04/10/12,Nektar to Host Investor and Analyst R&D Day in New York City,PRN04/02/12,"Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain",PRN03/28/12,Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS¬ (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis,PRN03/20/12,Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay,PRN03/05/12,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Healthcare Conference for 6-March-2012 10:00 AM ET,FCSTEV03/02/12,Nektar Therapeutics Announces Webcast of Presentation at the 32nd Annual Cowen and Company Healthcare Conference in Boston,PRN03/01/12,"Top Stock Alerts for Day Traders: JDS Uniphase, Kinross Gold, PulteGroup, Nektar Therapeutics, and New Gold",PRN02/29/12,Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results,PRN02/29/12,Nektar Therapeutics Announces Agreement to Sell CIMZIA¬ and MIRCERA¬ Royalties to Royalty Pharma for $124 Million,PRN02/27/12,Nektar Therapeutics(NKTR-US) Schedules Q4 2011 Earnings Call for 29-February-2012 5:00 PM ET,FCSTEV02/27/12,"Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting",PRN02/24/12,Nektar Therapeutics(NKTR-US) Schedules Q4 2011 Earnings Release for 29-February-2012 After Market Hours ET,FCSTEV02/24/12,"Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets",PRN01/13/12,"A Forward Look, the Year Ahead -- Featured Research on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics ",INW01/05/12,Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A,PRN01/05/12,Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A,BW01/04/12,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN01/03/12,Nektar Therapeutics(NKTR-US) Schedules JPMorgan Healthcare Conference for 11-January-2012 11:30 AM ET,FCSTEV12/13/11,"Nektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of NKTR-181, a Novel Opioid Analgesic Molecule to Treat Chronic Pain",PRN12/12/11,Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR-102 in Women with Metastatic Breast Cancer,PRN12/08/11,Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis,PRN11/15/11,NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer,PRN11/14/11,Nektar Therapeutics(NKTR-US) Schedules AACR-NCI-EORTC International Conference for 15-November-2011 3:30 PM ET,FCSTEV11/14/11,Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011,PRN11/02/11,Nektar Therapeutics Reports Third Quarter 2011 Financial Results,PRN10/26/11,Nektar Therapeutics(NKTR-US) Schedules Q3 2011 Earnings Call for 2-November-2011 5:00 PM ET,FCSTEV10/26/11,Nektar Therapeutics(NKTR-US) Schedules Q3 2011 Earnings Release for 2-November-2011 After Market Hours ET,FCSTEV10/26/11,"Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets",PRN10/14/11,Nektar Therapeutics(NKTR-US) Schedules BioCentury Newsmakers in the Biotech Industry Conference for 21-October-2011 10:30 AM ET,FCSTEV09/21/11,"Nektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting",PRN09/20/11,"Global Situation & Resulting Influences - Research Report on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics ",INW09/15/11,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 20-September-2011 10:00 AM ET,FCSTEV09/14/11,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City",PRN09/09/11,Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium,PRN09/08/11,"Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain",PRN08/08/11,Nektar Therapeutics(NKTR-US) Schedules ASCO Breast Cancer Symposium - Abstract #269 for 9-September-2011,FCSTEV08/04/11,Nektar Therapeutics Reports Second Quarter 2011 Financial Results,PRN07/27/11,Nektar Therapeutics(NKTR-US) Schedules Q2 2011 Earnings Call for 4-August-2011 5:00 PM ET,FCSTEV07/27/11,Nektar Therapeutics(NKTR-US) Schedules Q2 2011 Earnings Release for 4-August-2011 After Market Hours ET,FCSTEV07/27/11,"Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets",PRN07/25/11,TARIS Appoints Christopher Searcy as the Company's Chief Business Officer,BW07/18/11,NKTR-102 Receives Positive Opinion From EMA COMP for Orphan Medicinal Product Designation in Ovarian Cancer,PRN06/07/11,Data from Phase 1 Study of NKTR-181 Demonstrate Proof-of-Concept for Nektar's Novel Opioid Analgesic Candidate,PRN06/05/11,NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil¬,PRN06/04/11,NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting,PRN06/01/11,Nektar Therapeutics(NKTR-US) Schedules Jefferies & Co. Global Healthcare Conference for 7-June-2011 10:00 AM ET,FCSTEV06/01/11,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York,PRN05/19/11,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #5047 for 5-June-2011 9:00 AM ET,FCSTEV05/19/11,"Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #2598, Poster Board: #8E for 6-June-2011 9:00 AM ET",FCSTEV05/19/11,"Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #1034, Poster Board #24 for 4-June-2011 3:00 PM ET",FCSTEV05/19/11,Nektar Therapeutics(NKTR-US) Schedules Investor and Analyst Meeting for 6-June-2011 8:30 AM ET,FCSTEV05/18/11,Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting,PRN04/27/11,Nektar Therapeutics Reports First Quarter 2011 Financial Results,PRN04/22/11,Nektar Therapeutics(NKTR-US) Schedules Bank of America Merrill Lynch Health Care Conference for 12-May-2011 2:50 PM ET,FCSTEV04/21/11,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Health Care Conference for 2-May-2011 11:20 AM ET,FCSTEV04/21/11,"FDA Grants Orphan Drug Designation for Nektar's Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer",PRN04/18/11,Nektar Therapeutics(NKTR-US) Schedules Q1 2011 Earnings Release for 27-April-2011 After Market Hours ET,FCSTEV04/18/11,Nektar Therapeutics(NKTR-US) Schedules Q1 2011 Earnings Call for 27-April-2011 5:00 PM ET,FCSTEV04/18/11,"Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets",PRN03/21/11,"Nektar Initiates Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Pain",PRN03/15/11,AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation,PRN03/01/11,Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results,PRN03/01/11,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Health Care Conference for 8-March-2011 11:00 AM ET,FCSTEV03/01/11,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston,PRN02/21/11,Nektar Therapeutics(NKTR-US) Schedules Barclays Capital Global Healthcare Conference for 17-March-2011 8:30 AM ET,FCSTEV02/17/11,Nektar Therapeutics(NKTR-US) Schedules Q4 2010 Earnings Call for 1-March-2011 5:00 PM ET,FCSTEV02/17/11,Nektar Therapeutics(NKTR-US) Schedules Q4 2010 Earnings Release for 1-March-2011 After Market Hours ET,FCSTEV02/17/11,"Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets",PRN01/24/11,Nektar Therapeutics Completes Public Offering of Common Stock,PRN01/19/11,Nektar Therapeutics Prices Public Offering of Common Stock,PRN01/18/11,Nektar Therapeutics Announces Proposed Public Offering of Common Stock,PRN01/13/11,"Zacks Sell List Highlights: FreightCar America, Brookfield Asset Management, Becton, Dickinson and Co. and Nektar Therapeutics",PRN01/05/11,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/22/10,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Healthcare Conference for 11-January-2011 11:30 AM ET,FCSTEV12/12/10,NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients,PRN12/09/10,Nektar Therapeutics(NKTR-US) Schedules AACR San Antonio Breast Cancer Symposium for 12-December-2010 10:00 AM ET,FCSTTS12/09/10,Phase 2 Clinical Data on NKTR-102 in Metastatic Breast Cancer to Be Presented at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium,PRN11/13/10,Nektar Announces Two Preclinical Data Presentations at Society for Neuroscience 40th Annual Meeting: Neuroscience 2010,PRN11/04/10,Nektar Therapeutics Reports Third Quarter 2010 Financial Results,PRN10/29/10,Nektar Therapeutics(NKTR-US) Schedules Q3 2010 Earnings Call for 4-November-2010 5:00 PM ET,FCSTTS10/28/10,Nektar Therapeutics(NKTR-US) Schedules Q3 2010 Earnings Release for 4-November-2010 After Market Hours ET,FCSTTS10/28/10,"Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets",PRN10/17/10,Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010,PRN10/15/10,"NKTR-181, A Mu-Opioid Analgesic With a Novel Molecular Structure, Demonstrates Slower Entry Rate Into the Brain and Reduced CNS Side Effects",PRN09/17/10,Nektar Therapeutics To Present at the UBS 2010 Global Life Sciences Conference,PRN09/15/10,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 21-September-2010 11:00 AM ET,FCSTTS08/31/10,BioSpace Highlights Northern California's Growing Life Science Region,PRN07/28/10,Nektar Therapeutics Reports Second Quarter 2010 Financial Results,PRN07/21/10,Nektar Therapeutics(NKTR-US) Schedules Q2 2010 Earnings Call for 28-July-2010 5:00 PM ET,FCSTTS07/21/10,Nektar Therapeutics(NKTR-US) Schedules Q2 2010 Earnings Release for 28-July-2010 After Market Hours ET,FCSTEV07/21/10,"Nektar to Announce Financial Results for the Second Quarter of 2010 On Wednesday, July 28, 2010, After Close of U.S.-Based Financial Markets",PRN07/06/10,NKTR-102 Demonstrates Superior Activity to Irinotecan in Nonclinical Studies Presented at ESMO 12th World Congress on Gastrointestinal Cancer,PRN06/24/10,Nektar Announces Dosing of First Patients in Phase 1 Clinical Study of NKTR-102 in Combination With 5-Fluorouracil/Leucovorin,PRN06/09/10,Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer,PRN06/07/10,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology for 7-June-2010 7:30 AM ET,FCSTTS06/06/10,NKTR-102 Has High Response Rate and Sustained Clinical Benefit in 48 Percent of Women with Platinum-Resistant/Refractory Ovarian Cancer,PRN06/03/10,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Life Sciences Conference for 9-June-2010 10:00 AM ET,FCSTTS06/03/10,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2010 Global Life Sciences Healthcare Conference in New York,PRN05/20/10,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology - NKTR-102 for 6-June-2010 12:15 PM ET,FCSTTS05/20/10,NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting,PRN05/05/10,Nektar Therapeutics Reports First Quarter 2010 Financial Results,PRN04/27/10,Nektar Therapeutics(NKTR-US) Schedules Q1 2010 Earnings Call for 5-May-2010 5:00 PM ET,FCSTTS04/27/10,Nektar Therapeutics(NKTR-US) Schedules Q1 2010 Earnings Release for 5-May-2010 After Market Hours ET,FCSTTS04/27/10,"Nektar to Announce Financial Results for the First Quarter of 2010 on Wednesday, May 5, 2010, After Close of U.S.-Based Financial Markets",PRN03/08/10,Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer,PRN03/03/10,Nektar Therapeutics(NKTR-US) Schedules Cowen & Company Health Care Conference for 8-March-2010 1:00 PM ET,FCSTTS03/02/10,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the 30th Annual Cowen and Company Healthcare Conference in Boston,PRN03/02/10,Nektar Therapeutics Reports Year-End 2009 Financial Results,PRN02/24/10,Nektar Therapeutics(NKTR-US) Schedules Q4 2009 Earnings Call for 2-March-2010 5:00 PM ET,FCSTTS02/23/10,Nektar Therapeutics(NKTR-US) Schedules Q4 2009 Earnings Release for 2-March-2010 After Market Hours ET,FCSTTS02/23/10,"Nektar to Announce Year-End 2009 Financial Results on Tuesday, March 2, 2010, After Close of U.S.-Based Financial Markets",PRN02/02/10,Nektar Therapeutics Appoints R. Scott Greer to Board of Directors,PRN01/14/10,"Aggressive Traders Alert: Wound Management Technologies -- January 14, 2010 ",INW01/12/10,Nektar Therapeutics Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer,PRN01/11/10,Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors,PRN01/06/10,"Nektar Therapeutics Names Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer",PRN01/06/10,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN12/29/09,Nektar Therapeutics(NKTR-US) Schedules JPMorgan Healthcare Conference for 12-January-2010 1:00 PM ET,FCSTEV12/14/09,Dennis Winger Joins Nektar Therapeutics' Board of Directors,PRN11/30/09,"Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer",PRN11/04/09,Nektar Therapeutics Reports Third Quarter 2009 Financial Results,PRN10/29/09,Nektar Therapeutics(NKTR-US) Schedules Q3 2009 Earnings Release for 4-November-2009 After Market Hours ET,FCSTEV10/29/09,"Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets",PRN10/29/09,"Alexandria Real Estate Equities, Inc. Provides Update",PRN10/28/09,Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer,PRN10/27/09,Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego,PRN10/26/09,Nektar Therapeutics(NKTR-US) Schedules Q3 2009 Earnings Call for 4-November-2009 5:00 PM ET,FCSTEV10/10/09,Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix,PRN09/22/09,Nektar Therapeutics (NKTR) President and Chief Executive Officer to Ring The NASDAQ Stock Market Closing Bell,PMZ09/22/09,NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress,PRN09/21/09,Nektar Therapeutics(NKTR-US) Schedules Business Update Call for 21-September-2009 8:30 AM ET,FCSTEV09/21/09,Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119,PRN09/21/09,AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation,PRN09/18/09,Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City,PRN09/13/09,Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118,PRN09/10/09,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 22-September-2009 10:30 AM ET,FCSTEV08/05/09,"International Tower Hill Delineates Major New Zone of Gold Mineralization at Livengood Gold Project, Alaska",INW08/04/09,Nektar Therapeutics Reports Second Quarter 2009 Financial Results,PRN08/04/09,"International Tower Hill Mines Signs Agreement to Acquire 100% Interest in North Bullfrog Project, Nevada",INW08/02/09,Nektar Therapeutics(NKTR-US) Schedules BMO Capital Markets Focus on Healthcare Conference for 5-August-2009 1:45 PM ET,FCSTEV07/31/09,Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City,PRN07/31/09,Nektar Therapeutics(NKTR-US) Schedules Q2 2009 Earnings Call for 4-August-2009 5:00 PM ET,FCSTEV07/31/09,Nektar Therapeutics(NKTR-US) Schedules Q2 2009 Earnings Release for 4-August-2009 After Market Hours ET,FCSTEV07/31/09,"Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets",PRN07/20/09,"International Tower Hill Announces Results for First 16 Holes of Summer 2009 Drill Program at Livengood Gold Deposit, Alaska",INW07/10/09,International Tower Hill Receives Share Ownership Top-Up Notice From AngloGold Ashanti,INW06/30/09,International Tower Hill Mines Retains Renmark Financial Communications Inc.,INW06/26/09,"Free Growth Strategy Report on MELI, CBST, NKTR, IVAN, SBIB and REXX by MaybachFinancial.com",INW06/25/09,"International Tower Hill Announces Resource Update at Livengood, Alaska",INW06/10/09,"International Tower Hill Mines Livengood Gold Project, Alaska",INW06/09/09,"Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer",PRN06/01/09,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 11-June-2009 5:00 PM ET,FCSTEV05/15/09,"TheFortuneFinancial.com Initializes Free Analyst Research on NKTR, DPTR, NCMI and INSM",INW05/14/09,Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis,PRN05/13/09,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Healthcare Conference for 18-May-2009 1:45 PM ET,FCSTEV05/12/09,Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston,PRN05/12/09,"International Tower Hill Announces Latest Winter Program Drill Results From NE and SW Zones, Livengood Gold Deposit, Alaska",INW05/06/09,Nektar Therapeutics Reports First Quarter 2009 Financial Results,PRN04/30/09,Nektar Therapeutics(NKTR-US) Schedules Q1 2009 Earnings Call for 6-May-2009 5:00 PM ET,FCSTEV04/29/09,Nektar Therapeutics(NKTR-US) Schedules Q1 2009 Earnings Release for 6-May-2009 After Market Hours ET,FCSTEV04/29/09,"Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets",PRN04/23/09,"International Tower Hill Reports Extension of High Grade SW Zone and Expansion of Livengood Gold Deposit, Alaska",INW04/22/09,NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR,PRN04/15/09,International Tower Hill's Livengood Project Returns 89% Gold Recovery From Recent Metallurgical Testwork,INW04/02/09,Nektar Therapeutics(NKTR-US) Schedules BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference for 2-April-2009 11:00 AM ET,FCSTEV03/12/09,Steve Aaker Joins the Board of Directors of International Tower Hill Mines Ltd.,INW03/10/09,Nektar Therapeutics(NKTR-US) Schedules Cowen & Co. Health Care Conference for 16-March-2009 2:25 PM ET,FCSTEV03/10/09,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston",PRN03/10/09,"International Tower Hill Mines Ltd. Doubles Planned 2009 Drill Program for Livengood Gold Project, Alaska",INW03/04/09,"International Tower Hill Mines Ltd. Closes $10,500,000 Bought Deal Equity Financing",INW03/02/09,Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC),PRN02/24/09,Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results,PRN02/17/09,Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors,PRN02/12/09,International Tower Hill Mines Ltd. Announces Bought Deal Equity Financing,INW02/11/09,Nektar Therapeutics(NKTR-US) Schedules Q4 2008 Earnings Release for 24-February-2009,FCSTEV02/11/09,Nektar Therapeutics(NKTR-US) Schedules Q4 2008 Earnings Call for 2-March-2009 5:00 PM ET,FCSTEV02/11/09,"Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets",PRN02/09/09,"International Tower Hill Mines Livengood Gold Project, Alaska",INW01/29/09,Nektar Announces Retirement of Irwin Lerner from Board of Directors,PRN01/28/09,"International Tower Hill Mines Livengood Gold Project, Alaska",INW01/13/09,First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer,PRN01/13/09,International Tower Hill Continues to Expand Livengood Gold Deposit,INW01/05/09,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Healthcare Conference for 13-January-2009 1:00 PM ET,FCSTEV01/05/09,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco",PRN12/31/08,Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million,PRN12/31/08,Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million,PRN12/10/08,International Tower Hill Mines Ltd.: Livengood Gold Deposit Expands in all Directions,INW12/01/08,"ITH Discovers New High-grade Gold Mineralization on West Pogo Project, Alaska",INW11/25/08,"ITH & Redstar Gold Increase Holdings at North Bullfrog Project, Nevada",INW11/17/08,ITH's Multi-Million Ounce Livengood Gold Deposit Expanded by Step Out Drilling,INW11/06/08,Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results,PRN11/04/08,ITH Expands Chisna Porphyry Copper-Gold Belt With Multiple New Discoveries,INW10/29/08,"ITH Doubles Gold Resource at Livengood Project, Alaska",INW10/27/08,Nektar Therapeutics(NKTR-US) Schedules R&D Day for 12-November-2008 12:00 PM ET,FCSTEV10/27/08,Nektar Therapeutics to Webcast R&D Day on November 12th,PRN10/24/08,Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium,PRN10/23/08,Nektar Therapeutics(NKTR-US) Schedules Q3 2008 Earnings Release for 6-November-2008 After Market Hours ET,FCSTEV10/23/08,Nektar Therapeutics(NKTR-US) Schedules Q3 2008 Earnings Call for 6-November-2008 5:00 PM ET,FCSTEV10/23/08,"Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets",PRN10/23/08,"Technical Trade Alerts on Market Movers: AAPL, ICOG, NKTR, STSI, HA, AVGN",NEWS_ACW10/23/08,"Beacon Equity Issues Technical Trade Alerts on Market Movers: AAPL, ICOG, NKTR, STSI, HA, AVGN",PRN10/23/08,Positive Preclinical Data Demonstrating Anti-Tumor Activity of NKTR-105 (PEG-docetaxel) Presented at 20th EORTC-NCI-AACR Conference,PRN10/21/08,Nektar Therapeutics(NKTR-US) Schedules Acquisition of Novartis AG by Nektar Therapeutics Call for 21-October-2008 10:30 AM ET,FCSTEV10/21/08,"Beacon Equity Issues Technical Trade Alerts on Market Movers: INCY, DRRX, MDRX, NKTR, PRGN, AFFX",PRN10/20/08,"Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder",PRN10/20/08,"ITH Defines High-Grade Surface Copper-Gold Anomalies at BMP Project, Alaska",INW10/20/08,"Beacon Equity Issues Technical Trade Alerts on Market Movers: MFGD, LGDI, NGAS, SOLR, IILG, NKTR",PRN10/10/08,"Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes",PRN10/07/08,Nektar Therapeutics(NKTR-US) Schedules Natixis Bleichroeder Hidden Gems Conference for 13-October-2008 2:30 PM ET,FCSTEV10/07/08,Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City,PRN09/30/08,Multiple Gold Intersections Expand ITH's Livengood Deposit,INW09/16/08,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Science Conference for 23-September-2008 10:30 AM ET,FCSTEV09/16/08,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City",PRN09/04/08,International Tower Hill Mines Ltd.: Livengood Deposit Significantly Expands High Grade Core Zones,INW09/02/08,"ITH Announces Initial Resource Estimate for Mayflower Deposit at North Bullfrog Project, Nevada",INW08/06/08,"Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer",PRN08/06/08,Nektar Therapeutics Announces Second Quarter 2008 Results,PRN07/31/08,Nektar Therapeutics(NKTR-US) Schedules Q2 2008 Earnings Call for 6-August-2008 5:00 PM ET,FCSTEV07/30/08,Nektar Therapeutics(NKTR-US) Schedules Q2 2008 Earnings Release for 6-August-2008 After Market Hours ET,FCSTEV07/30/08,"Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets",PRN07/23/08,"ITH Intersects Additional Bulk-Tonnage-Grade Gold Intercepts at Livengood Deposit, Alaska",INW07/15/08,International Tower Hill Amends Options,INW06/26/08,"ITH Drills 202.69 Metres of 1.37 g/t Gold at Livengood Deposit, Alaska",INW06/17/08,"Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes",PRN06/10/08,"ITH Acquires 100% Interest in the Terra and LMS Projects, Alaska from AngloGold Ashanti Exploration (U.S.A.) Inc.",INW06/02/08,Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan),PRN06/02/08,"New Positive Data Announced for NKTR-102 (PEG-irinotecan), Highlights Promise of Nektar's Innovative Small Molecule PEG-Oncolytics",PRN05/30/08,"Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)",PRN05/27/08,Nektar Therapeutics(NKTR-US) Schedules NKTR-102 Phase 1 Trial Results Call for 2-June-2008 7:30 PM ET,FCSTEV05/27/08,"ITH Expands Mayflower Deposit at North Bullfrog Project, Nevada",INW05/22/08,Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit,PRN05/19/08,Amikacin Inhale Shows Promising Results in Phase II Study,PRN05/16/08,Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings,PRN05/13/08,"ITH Outlines Large Geophysical Anomalies Associated With High Copper-Gold-Silver Mineralization on BMP Project, Alaska",INW05/12/08,"Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress",PRN05/12/08,"ITH Commences 42,000 Metre Resource Drilling Program at the Livengood Gold Project, Alaska",INW05/07/08,Nektar Therapeutics Announces First Quarter 2008 Results,PRN05/07/08,Nektar Receives Patent Covering Pulmonary Targeted Antibiotics,PRN05/07/08,NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting,PRN04/30/08,Nektar Therapeutics(NKTR-US) Schedules Q1 2008 Earnings Release for 7-May-2008 After Market Hours ET,FCSTEV04/30/08,Nektar Therapeutics(NKTR-US) Schedules Q1 2008 Earnings Call for 7-May-2008 5:00 PM ET,FCSTEV04/30/08,"Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets",PRN04/29/08,"ITH Intersects New Zone of Mineralization at its North Bullfrog Project, Nevada",INW04/23/08,FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform,PRN04/14/08,"BellwetherReport.com Initiates Analyst Coverage on CPHD, STSA, CYTR and NKTR",INW04/14/08,ITH Discovers Bulk Tonnage Gold System in Nevada,INW04/14/08,Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting,PRN04/10/08,Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings,PRN04/09/08,"BellwetherReport.com Free Analyst Review for NKTR, MNKD, EPMD and AMGI",INW04/09/08,"ITH Sells Interest in South Estelle Project, Alaska to Millrock Resources Inc.",INW04/09/08,Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients,PRN03/26/08,"ITH Acquires Strategic Base Metals Property Adjoining BMP Project, Alaska",INW03/20/08,QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised),PRN03/19/08,QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes,PRN02/27/08,Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results,PRN02/21/08,"Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets",PRN02/18/08,"ITH Reports Multi-Million Ounce Inferred Gold Resource at Livengood Project, Alaska",INW02/13/08,"ITH Reports Initial Inferred Gold Resource at LMS Project, Alaska",INW02/12/08,Nektar Therapeutics(NKTR-US) Schedules Q4 2007 Earnings Call for 27-February-2008 5:00 PM ET,FCSTEV02/12/08,Nektar Therapeutics(NKTR-US) Schedules Q4 2007 Earnings Release for 27-February-2008,FCSTEV02/12/08,Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization,PRN02/12/08,"Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Company's Board of Directors",PRN02/07/08,"ITH Reports Initial Inferred Resource at Terra Project, Alaska",INW01/30/08,"Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference for 5-February-2008 1:00 PM ET",FCSTEV01/29/08,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City",PRN01/29/08,ITH Outlines Planned US$11M Exploration Program For 2008,INW01/16/08,ITH Grants Incentive Stock Options,INW01/08/08,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Chase & Co Healthcare Conference for 8-January-2008 4:30 PM ET,FCSTEV01/08/08,"ITH Defines New Surface Gold Targets and Progresses Toward First Resource Calculation on LMS Project, Alaska",INW01/08/08,Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer,PRN01/08/08,Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction,PRN01/07/08,Baxter Announces Recombinant Factor IX Development Program For Hemophilia B,PRN01/02/08,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Chase & Co Healthcare Conference for 8-January-2008 7:30 PM ET,FCSTEV01/02/08,Nektar Therapeutics' President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference,PRN12/20/07,Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia,PRN12/11/07,Nektar Promotes John Nicholson to Serve as Chief Financial Officer,PRN12/10/07,"ITH Acquires High-Grade Gold Vein System Adjacent to Its North Bullfrog Project, Nevada",INW11/29/07,"International Tower Hill Mines Ltd.: Trenching Intersects High-Grade Gold Veins on Coffee Dome Project, Alaska",INW11/28/07,Nektar Therapeutics(NKTR-US) Schedules Bank of Montreal Focus on Healthcare Conference for 5-December-2007 10:30 AM ET,FCSTEV11/28/07,Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference,PRN11/27/07,ITH Expands SE Chisna Porphyry Copper-Gold Target,INW11/16/07,ITH's Livengood Gold Deposit Continues to Grow; Step-Out Drilling Dramatically Expands Bulk Tonnage Potential,INW11/15/07,ITH Discovers Gold Endowed Vein System at Painted Hills Project in Nevada,INW11/14/07,Nektar's Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York,PRN11/13/07,Nektar Therapeutics(NKTR-US) Schedules R&D Day for 14-November-2007 12:00 PM ET,FCSTEV11/13/07,Nektar Therapeutics to Webcast R&D Day on November 14th,PRN11/13/07,Pfizer and Nektar Reach Agreement on Exubera(R),PRN11/08/07,"ITH Expands Terra High-Grade Gold Project, Alaska",INW11/07/07,Nektar Therapeutics Announces Third Quarter 2007 Financial Results,PRN10/31/07,Nektar Therapeutics(NKTR-US) Schedules Q3 2007 Earnings Call for 7-November-2007 5:00 PM ET,FCSTEV10/31/07,Nektar Therapeutics(NKTR-US) Schedules Q3 2007 Earnings Release for 7-November-2007 After Market Hours ET,FCSTEV10/31/07,"Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets",PRN10/25/07,NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models,PRN10/19/07,"Market Pulse Announces Its Hot Stock Alerts for Friday, October 19, 2007: PEP, DELL, ORCL, NKTR",INW10/18/07,Nektar Therapeutics Issues Statement on Exubera,PRN10/18/07,ITH Further Defines Mineralization at South Estelle,INW10/10/07,Nektar Therapeutics(NKTR-US) Schedules AACR-NCI-EORTC International Conference for 25-October-2007 8:30 PM ET,FCSTEV10/10/07,Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference,PRN10/02/07,Nektar Therapeutics(NKTR-US) Schedules Biotechnology Industry Organization Investor Forum for 10-October-2007 1:15 PM ET,FCSTEV10/02/07,Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum,PRN09/27/07,"ITH Continues to Significantly Expand Sediment Hosted Mineralization at Livengood Gold Deposit, Alaska",INW09/27/07,NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor Activity and Improved Pharmacokinetic Profile in Preclinical Studies Presented at ECCO,PRN09/26/07,Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting,PRN09/24/07,"ITH Reports Continued High-Grade Gold Intersections from Terra Project, Alaska",INW09/18/07,"ITH Reports Initial Drilling Results at West Tanana Project, Central Alaska",INW09/18/07,Nektar Therapeutics Creates New PEGylation and Pulmonary Research Units to Drive Innovative Technology-Based Product Pipeline,PRN09/13/07,"ITH Begins Drilling on Painted Hills Project in Nevada, Early Encouraging Results",INW09/13/07,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 26-September-2007 11:00 AM ET,FCSTEV09/13/07,Nektar Therapeutics President and CEO Howard Robin to Present at 2007 UBS Global Life Sciences Conference,PRN09/11/07,"ITH Discovers New Copper-Gold Porphyry System on Its Chisna Project, Alaska",INW09/10/07,Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting,PRN09/06/07,Pearl Therapeutics Raises $15.5 Million in Private Financing,PRN09/05/07,"ITH Reports Initial Drilling Results from its North Bullfrog Project, Nevada",INW08/29/07,Nektar Therapeutics Appoints Lutz Lingnau as New Board Member,PRN08/23/07,Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer,PRN08/08/07,Nektar Therapeutics Announces Second Quarter 2007 Financial Results,PRN08/06/07,Bayer HealthCare and Nektar Therapeutics Launch Global Development and Commercialization Agreement to Fight Gram-Negative Pneumonias,PRN08/01/07,"ITH Discovers New Sediment Hosted High-Grade Gold Mineralization at Livengood Project, Alaska",INW07/31/07,"ITH to Begin Trading on the AMEX on August 3, 2007",INW07/26/07,Nektar Therapeutics(NKTR-US) Schedules European Cancer Conference for 27-September-2007 2:00 AM ET,FCSTEV07/26/07,Anti-Tumor Activity and Pharmacokinetic Properties of NKTR-102 (PEG-irinotecan) to be Presented at Upcoming Oncology Meeting,PRN07/26/07,First Peer-Reviewed Preclinical and Early Phase 1 Results for NKTR-118 (oral PEG-naloxol) to be Presented at Upcoming Pharmacology and Pain Management Meetings,PRN07/25/07,Nektar Therapeutics(NKTR-US) Schedules Q2 2007 Earnings Release for 8-August-2007 After Market Hours ET,FCSTEV07/25/07,Nektar Therapeutics(NKTR-US) Schedules Q2 2007 Earnings Call for 8-August-2007 5:00 PM ET,FCSTEV07/25/07,"Nektar to Announce Second Quarter 2007 Financial Results on Wednesday, August 8, 2007, After the Close of U.S. Financial Markets",PRN06/21/07,ITH Completes Airborne Survey at Chisna Cu-Au Project,INW06/19/07,ITH Signs Option Agreement to Earn Interest in New High-Grade Alaskan Gold Project,INW06/14/07,"ITH Expands New High Grade Gold Zones with Ongoing Drill Program at its Bulk Tonnage Livengood Project, Alaska",INW06/12/07,"ITH Begins Drilling Programs at Terra and West Tanana Projects, Alaska",INW06/06/07,Nektar Therapeutics(NKTR-US) Schedules Annual Shareholder Meeting for 7-June-2007 4:00 PM ET,FCSTEV06/01/07,(OTC: TFZP) Introduces Automated Hydration Equipment for High Volume Perishable Shipping,INW05/25/07,Nektar Therapeutics President and CEO Howard Robin to Present at Bank of America 2007 Health Care Conference,BW05/24/07,Ronald Sheardown and Michael Bartlett Join Board of Directors,INW05/24/07,Nektar Therapeutics(NKTR-US) Schedules PEGylation and Pulmonary Drug Development Update Call for 24-May-2007 9:00 AM ET,FCSTEV05/23/07,CORRECTING and REPLACING Nektar Announces New Organizational Structure and Spending Reduction Initiatives to Solidify the Company's Leadership Position in PEGylation and Pulmonary Drug Development,BW05/22/07,Nektar Therapeutics(NKTR-US) Schedules Banc of America Healthcare Conference for 31-May-2007 7:40 PM ET,FCSTEV05/21/07,Nektar Threraputics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference<>Pulmonary Antibiotics Platform for Ventilated Patients with Hospital Acquired Pneumonia. (Graphic: Business Wire),BW05/17/07,Nektar Therapeutics(NKTR-US) Schedules American Thoracic Society International Conference for 21-May-2007 11:15 AM ET,FCSTEV05/11/07,(OTC: GNLM) Announced Stock Split Record Date,INW05/10/07,"ITH Closes $2,880,000 Non-Brokered Private Placement",INW05/10/07,"ITH Closes $14,650,800 Brokered Private Placement",INW05/09/07,Nektar Therapeutics Announces First Quarter 2007 Results,BW05/09/07,Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be Presented at American Thoracic Society International Conference,BW04/27/07,Nektar Therapeutics(NKTR-US) Schedules Morgan Stanley Global Healthcare Conference for 3-May-2007 1:30 PM ET,FCSTEV04/27/07,Nektar Executives Participating In Upcoming Investor Conferences,BW04/26/07,Nektar Therapeutics(NKTR-US) Schedules Q1 2007 Earnings Call for 9-May-2007 4:30 PM ET,FCSTEV04/24/07,"Nektar to Announce First Quarter 2007 Financial Results On Wednesday, May 9, 2007, After the Close of U.S. Financial Markets",BW04/19/07,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Securities Health Care Conference for 2-May-2007 1:00 PM ET,FCSTEV04/16/07,"International Tower Hill Mines Ltd. Increases Brokered Private Placement to $14,650,800",INW04/12/07,ITH Announces the Beginning of Drilling at Livengood and Outlines USD7M North American Exploration Program for 2007,INW04/11/07,"International Tower Hill Mines Ltd. Negotiates $2,880,000 Non-Brokered Private Placement",INW04/10/07,"International Tower Hill Mines Ltd. Negotiates $9,600,000 Brokered Private Placement",INW04/09/07,Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics,BW04/05/07,Nektar Therapeutics(NKTR-US) Schedules CIBC Biotechnology & Specialty Pharmaceuticals Conference for 11-April-2007 11:30 AM ET,FCSTEV04/04/07,CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Nektar Corporate Presentation,BW03/16/07,ITH Signs Option Agreements to Earn Interests in Two Gold Projects in Nevada,INW03/13/07,Nektar Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG-irinotecan) for Potential to Treat Patients with Refractory Solid Tumors,BW03/13/07,"ITH Acquires Key Land Position on Its Coffee Dome Project, Alaska and Dramatically Expands Its Gold Soil Anomaly",INW03/07/07,Nektar Therapeutics(NKTR-US) Schedules Lehman Global Healthcare Conference for 20-March-2007 1:30 PM ET,FCSTEV03/07/07,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Health Care Conference for 13-March-2007 2:30 PM ET,FCSTEV03/07/07,Nektar to Present at Cowen & Company and Lehman Brothers Conferences,BW02/28/07,Nektar Announces Financial Results for the Year and Fourth Quarter 2006,BW02/17/07,Nektar Therapeutics(NKTR-US) Schedules Q1 2007 Earnings Release for 9-May-2007 After Market Hours ET,FCSTEV02/14/07,Nektar Therapeutics(NKTR-US) Schedules Q4 2006 Earnings Call for 28-February-2007 5:00 PM ET,FCSTEV02/14/07,Nektar Sets Announcement Date and Conference Call for Year End and Fourth Quarter 2006,BW02/02/07,Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Pharmaceutical Biotechnology & Medical Device Conference for 7-February-2007 1:00 PM ET,FCSTEV02/01/07,"Merrill Lynch 2007 Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Nektar Corporate Presentation",BW01/26/07,"ITH Continues to Expand LMS Deposit, Alaska",INW01/23/07,"ITH Intercepts New High Grade Gold Zone at its Bulk Tonnage Livengood Project, Alaska",INW01/08/07,Nektar Appoints Howard W. Robin President and CEO,BW12/14/06,Nektar Reports That Court Denies Novo Nordisk's Motion for Preliminary Injunction Against Exubera,BW12/07/06,"ITH Discovers Bulk Tonnage Porphyry Related Gold System at its Blackshell Project, Alaska",INW11/28/06,Advisory: BMO Capital Markets Focus on Healthcare Conference to Webcast Nektar Corporate Presentation,BW11/27/06,ITH Defines New Copper-Gold-Silver System with Bulk Tonnage Potential on its Chisna Project in Alaska,INW11/16/06,"ITH Intersects 4.2 Metres of 22.3 g/t Gold on Major Extension of the Vein System on the Terra Project, Alaska",INW11/09/06,"ITH Confirms Presence of a Major Gold Target on its West Tanana Project, Alaska",INW11/02/06,Nektar Announces Third Quarter 2006 Financial Results,BW11/01/06,Nektar Therapeutics(NKTR-US) Schedules CIBC Healthcare Conference for 7-November-2006 10:20 AM ET,FCSTEV11/01/06,Nektar Therapeutics(NKTR-US) Schedules Lehman Brothers Small Cap Conference for 17-November-2006 12:20 PM ET,FCSTEV11/01/06,"Nektar to Present at Three Conferences: Cowen & Company 7th Annual Global Health Care Conference, CIBC 17th Annual Healthcare Conference and Lehman Brothers Small Cap Conference",BW10/21/06,Nektar Therapeutics(NKTR-US) Schedules Q4 2006 Earnings Release for 28-February-2007 After Market Hours ET,FCSTEV10/19/06,Nektar Therapeutics(NKTR-US) Schedules Q3 2006 Earnings Call for 2-November-2006 5:00 PM ET,FCSTEV10/19/06,Advisory: Nektar Sets Announcement Date and Conference Call for the Third Quarter 2006,BW10/11/06,"ITH Consolidates Livengood Gold Project, Alaska Tests Bulk Tonnage Potential With 2500m Diamond Drillhole Program",INW10/03/06,Nektar Therapeutics Issues Statement on Whistle-Blower Proceeding Status,BW10/03/06,A Sarbanes-Oxley Whistleblower Action Against Nektar Therapeutics -- NKTR,INW09/29/06,"ITH drilling Intersects 1540 g/t '49.5 ounces/t' Gold over 0.8 Metres at the LMS Project, Alaska",INW09/27/06,International Tower Hill Mines Ltd.: 2006 Annual Meeting Results,INW09/24/06,Complete Auto (OTC PK: ECFL) Trained by eBay Motors,INW09/21/06,CORRECTING and REPLACING Zelos and Nektar Announce Start of Phase 1 Trial of Inhaled Ostabolin-C(TM) for Osteoporosis,BW09/18/06,International Tower Hill Launches New Corporate Website,INW09/18/06,European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk,BW09/14/06,Nektar Reports that Pfizer Announced New Analyses Showing that Exubera Is Effective in Diabetes Patients Who Have Respiratory Infections or Who are Exposed to Passive Cigarette Smoke,BW09/13/06,"International Tower Hill Acquires West Tanana Project, Alaska",INW09/12/06,Exubera Hailed as Innovation in Prestigious European and American Awards,BW09/11/06,"Nektar to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medtech Conference, Oppenheimer Diabetes Conference and UBS Investment Bank 2006 Global Life Sciences Conference",BW08/03/06,Nektar Announces Second Quarter 2006 Results,BW07/26/06,Nektar Closes Its Bradford UK Site; Company Focusing on Development of Products Using its Drug Delivery Technology,BW07/24/06,Nektar Therapeutics(NKTR-US) Schedules BMO Capital Markets Healthcare Conference for 6-December-2006 4:00 PM ET,FCSTEV07/24/06,"Nektar Announces Receipt of $17.6 Million Payment From Affymax, Inc. Under Agreement for Nektar Advanced PEGylation Technology; Cash Payment Resulting From Affymax and Takeda Signing Global Agreement for Hematide(TM) for the Treatment of Anemia",BW07/22/06,Nektar Therapeutics(NKTR-US) Schedules Q3 2006 Earnings Release for 2-November-2006 After Market Hours ET,FCSTEV07/20/06,Nektar Therapeutics(NKTR-US) Schedules Cowen & Co. Global Health Care Conference for 7-November-2006 2:40 AM ET,FCSTEV07/20/06,Nektar Therapeutics(NKTR-US) Schedules Oppenheimer Diabetes Investment Conference for 21-September-2006 11:30 AM ET,FCSTEV07/20/06,Nektar Reports That Pfizer to Introduce Exubera in U.S. With a Comprehensive Education Program,BW07/19/06,Nektar Therapeutics(NKTR-US) Schedules Q2 2006 Earnings Call for 3-August-2006 5:00 PM ET,FCSTEV07/19/06,Advisory: Nektar Sets Announcement Date and Conference Call for the Second Quarter 2006,BW07/07/06,Nektar and University of Alabama in Huntsville Announce Agreement to Settle Litigation,BW06/28/06,Nektar Therapeutics(NKTR-US) Schedules Windhover Information Euro-Biotech Forum for 28-June-2006 10:10 AM ET,FCSTEV06/20/06,Nektar Therapeutics(NKTR-US) Schedules Drug Information Meeting for 20-June-2006 8:30 AM ET,FCSTEV06/14/06,Nektar Therapeutics(NKTR-US) Schedules Pacific Growth Equities Life Sciences Conference for 14-June-2006 11:30 AM ET,FCSTEV06/12/06,Nektar Reports Pfizer Announcement That New Studies Show More Than Half of Patients at Risk for or Suffering from Complications of Type 2 Diabetes Delay Insulin Injections -- Some More Than Four Years,BW06/10/06,Nektar Reports Pfizer Announcement of New Exubera Data; New Data from Two Large Phase III Trials Reinforce Exubera's Long-Term Efficacy and Safety in Adults with Type 1 or Type 2 Diabetes,BW05/23/06,Nektar Therapeutics(NKTR-US) Schedules Strategic Research Institute Specialty Pharma Global Summit for 23-May-2006 4:15 PM ET,FCSTEV05/23/06,Nektar Therapeutics(NKTR-US) Schedules Annual Stockholders Meeting for 1-June-2006 1:00 PM ET,FCSTEV05/23/06,Advisory: Nektar Therapeutics to Webcast its 2006 Annual Meeting of Stockholders,BW05/22/06,FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients; First Inhaled Anti-Fungal Therapy Under Development for Immunosuppressed Patients,BW05/13/06,Nektar Therapeutics(NKTR-US) Schedules TiEcon Conference for 13-May-2006 6:30 PM ET,FCSTEV05/12/06,Nektar Therapeutics(NKTR-US) Schedules Banc of America Securities Health Care Conference for 16-May-2006 7:40 PM ET,FCSTEV05/12/06,Bank of America Health Care Conference to Webcast Nektar Corporate Presentation,BW05/10/06,Nektar Announces First Quarter 2006 Results,BW05/06/06,Nektar Therapeutics(NKTR-US) Schedules Q2 2006 Earnings Release for 3-August-2006,FCSTEV05/01/06,Nektar Therapeutics(NKTR-US) Schedules Q1 2006 Earnings Call for 10-May-2006 5:00 PM ET,FCSTEV05/01/06,Nektar Therapeutics(NKTR-US) Schedules Morgan Stanley Healthcare Conference for 4-May-2006 2:15 PM ET,FCSTEV05/01/06,Advisory: Nektar Sets Announcement Date and Conference Call for the First Quarter 2006,BW04/28/06,Morgan Stanley Global Healthcare Unplugged Conference to Webcast Nektar Corporate Presentation,BW04/28/06,"Hot Stocks to Watch for Friday, April 28, 2006: Patent Protection for Core Drug Discovery and Toxicology Platform!",INW04/27/06,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Securities Care Conference for 2-May-2006 2:30 PM ET,FCSTEV04/27/06,Deutsche Bank 31st Annual Health Care Conference to Webcast Nektar Corporate Presentation,BW03/30/06,Nektar Therapeutics(NKTR-US) Schedules CIBC Biotechnology & Specialty Pharmaceuticals Conference for 5-April-2006 11:30 AM ET,FCSTEV03/30/06,ADVISORY: CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Nektar Corporate Presentation,BW03/20/06,Nektar Therapeutics(NKTR-US) Schedules Bear Biotech West Coast Confab for 23-March-2006 4:30 PM ET,FCSTEV03/20/06,Advisory: Bear Biotech West Coast Confab to Webcast Nektar Corporate Presentation,BW03/06/06,Nektar Therapeutics(NKTR-US) Schedules Lehman Brothers Global Health Care Conference for 9-March-2006 8:30 AM ET,FCSTEV03/06/06,Advisory: Ninth Annual Lehman Brothers Global Healthcare Conference to Webcast Nektar Corporate Presentation,BW03/03/06,Nektar Therapeutics(NKTR-US) Schedules SG Cowen & Company LLC Health Care Conference for 7-March-2006 1:30 PM ET,FCSTEV03/03/06,2006 SG Cowen & Co. Annual Health Care Conference to Webcast Nektar Corporate Presentation,BW02/28/06,Nektar Announces Financial Results for the Year and Fourth Quarter 2005,BW02/22/06,Nektar Therapeutics(NKTR-US) Schedules Q4 2005 Earnings Call for 28-February-2006 5:00 PM ET,FCSTEV02/21/06,Advisory: Nektar Sets Announcement Date and Conference Call for the Year and Fourth Quarter 2005,BW02/14/06,Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients,BW02/11/06,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Securities Small Cap Growth Conference for 16-February-2006 8:00 AM ET,FCSTEV02/10/06,2006 Deutsche Bank Small Cap Growth Conference to Webcast Nektar Corporate Presentation,BW02/10/06,Nektar Therapeutics(NKTR-US) Schedules BIO CEO & Investor Conference for 15-February-2006 2:00 PM ET,FCSTEV02/09/06,Advisory: BIO CEO and Investor Conference to Webcast Nektar Corporate Presentation,BW02/07/06,Nektar CEO to Retire; Executive Chairman Appointed Acting CEO,BW02/01/06,Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Drug Device and Biotechnology Conference for 8-February-2006 9:20 AM ET,FCSTEV02/01/06,Merrill Lynch to Webcast Nektar Corporate Presentation,BW01/27/06,"Pfizer Receives FDA Approval for Exubera, the First Inhaleable Form of Insulin for Controlling Type 1 and Type 2 Diabetes in Adults",BW01/26/06,European Commission Approves Exubera(R) (Inhaled Human Insulin) for Treatment of Type 1 and Type 2 Diabetes,BW01/19/06,Nektar Therapeutics Appoints New Chief Financial Officer,BW01/12/06,Nektar Reports Pfizer to Acquire the Sanofi-Aventis Worldwide Rights to Exubera(R) (Inhaled Human Insulin),BW12/20/05,Nektar Therapeutics(NKTR-US) Schedules US - Japan Symposium on Drug Delivery Systems for 20-December-2005 1:50 AM ET,FCSTEV12/06/05,Nektar Therapeutics(NKTR-US) Schedules Informed Investors Biotechnology & Healthcare Investor Forum for 7-December-2005 4:25 PM ET,FCSTEV12/06/05,ADVISORY: Nektar Presentation to Be Webcast at Informed Investors Biotechnology & Healthcare Investor Forum,BW11/11/05,Advisory: Lehman Brothers to Webcast Nektar's Corporate Presentation,BW11/11/05,Nektar Therapeutics(NKTR-US) Schedules Lehman Brothers Small Cap Conference for 18-November-2005 11:40 AM ET,FCSTEV11/08/05,Nektar Therapeutics(NKTR-US) Schedules BIO-Europe Partnering Conference for 8-November-2005 11:00 AM ET,FCSTEV11/07/05,Nektar Therapeutics(NKTR-US) Schedules S.G. Cowan and Co. Global Healthcare Conference for 9-November-2005 7:55 AM ET,FCSTEV11/07/05,Advisory: SG Cowen & Co. to Webcast Nektar's Corporate Presentation,BW11/03/05,Nektar Announces Third Quarter 2005 Financial Results,BW11/01/05,Nektar Therapeutics(NKTR-US) Schedules CIBC Healthcare Conference for 7-November-2005 2:30 PM ET,FCSTEV10/31/05,CIBC World Markets to Webcast Nektar's Corporate Presentation,BW10/28/05,Nektar Therapeutics(NKTR-US) Schedules Q3 2005 Earnings Call for 3-November-2005 5:00 PM ET,FCSTEV10/28/05,Advisory: Nektar Sets Announcement Date and Conference Call for Third Quarter 2005 Results,BW10/28/05,Nektar Reports on Pfizer and Sanofi-Aventis Statement on Status of Exubera,BW10/20/05,Nektar Announces Closing of Aerogen Acquisition,BW10/14/05,"MORNING UPDATE: Seven Summits Research issues alerts for UNH, NTAP, FDC, NKTR, and PGR...",PRN10/13/05,Nektar Therapeutics Reports Exubera(R) Receives Positive Opinion from CHMP for the Treatment of Type 1 and Type 2 Diabetes,BW10/05/05,"Chiron and Nektar Announce Initiation of Phase III Clinical Program Evaluating Tobramycin Inhalation Powder in Cystic Fibrosis Patients -- First of Two Pivotal Trials Begins, Second Planned for 2006<>Pocket-size TIP inhaler, with drug capsules (Photo: Business Wire)<>Pocket-size TIP inhaler (Photo: Business Wire)",BW10/01/05,Nektar Therapeutics(NKTR-US) Schedules Q1 2006 Earnings Release for 10-May-2006,FCSTEV09/29/05,Nektar Announces Inhaled Amphotericin B Product in Human Clinical Trials for Preventing Fatal Pulmonary Fungal Infections in Immunosuppressed Patients<>Nektar Therapeutics' inhaled amphotericin B product for preventing fatal pulmonary fungal infections in immunosuppressed patients is delivered in a pocket size inhaler. (Photo: Business Wire),BW09/29/05,Nektar Announces Inhaled Antibiotics Product to Prevent Pneumonia in Mechanically-Ventilated Patients,BW09/29/05,Baxter Announces Collaborations to Develop Longer Acting Forms of Blood Clotting Factors,PRN09/29/05,Nektar and Baxter Collaborate to Develop Novel Longer-Acting Forms of Blood Clotting Factors,BW09/27/05,Nektar Announces Exercise of Option to Purchase $40 Million of Convertible Subordinated Notes,BW09/26/05,Nektar Therapeutics(NKTR-US) Schedules Investor Day for 29-September-2005 11:00 AM ET,FCSTEV09/26/05,"Nektar to Webcast Investor Day Presentations on September 29, 2005",BW09/22/05,Nektar Therapeutics Announces Private Offering of Convertible Subordinated Notes,BW09/21/05,Nektar Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes,BW09/20/05,Nektar Therapeutics(NKTR-US) Schedules UBS Warburg Life Sciences Conference for 28-September-2005 8:30 AM ET,FCSTEV09/14/05,"Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference for 16-September-2005 10:00 AM ET",FCSTEV09/13/05,Advisory: Merrill Lynch to Webcast Nektar's Corporate Presentation,BW09/12/05,"MORNING UPDATE: Seven Summits Research issues alerts for RFMD, NKTR, RMBS, ATVI, and BA",PRN09/08/05,Nektar Announces Investor's Election to Acquire $8M of Nektar's Common Stock,BW09/08/05,Nektar Reports That FDA Advisory Committee Recommends Approval of Exubera(R) for Use in Adults with Type 1 and Type 2 Diabetes,BW09/08/05,Nektar Reports That Nasdaq Halted Trading of Nektar Common Stock Today; FDA Advisory Committee Meeting to Discuss Exubera(R) (Insulin (rDNA Origin) Powder for Oral Inhalation),BW09/06/05,Nektar Therapeutics(NKTR-US) Schedules ThinkEquity Growth Conference for 12-September-2005 4:30 PM ET,FCSTEV09/02/05,Advisory: ThinkEquity Partners LLC to Webcast Nektar's Corporate Presentation,BW08/23/05,Nektar Therapeutics Selects MetricStream,INW08/17/05,Nektar Closes $24 Million Common Stock Financing: Elects to Pay All Cash for Aerogen Acquisition,BW08/16/05,Nektar Announces $24 Million Common Stock Financing,BW08/15/05,Nektar to Acquire Aerogen to Broaden Pulmonary Technology Base and Strengthen Capabilities for Treatment in the Acute Care Setting,BW08/04/05,Nektar Therapeutics(NKTR-US) Schedules Q2 2005 Earnings Call for 4-August-2005 5:00 PM ET,FCSTEV08/04/05,Nektar Announces Second Quarter 2005 Results,BW07/28/05,Advisory: Nektar Sets Announcement Date and Conference Call for Second Quarter 2005 Results,BW07/28/05,Banc of America Securities to Webcast Nektar's Corporate Presentation,BW07/26/05,Nektar Announces Newly-Created Diabetes Group and General Manager,BW07/21/05,Nektar Therapeutics(NKTR-US) Schedules Banc of America Securities Specialty Pharmaceuticals Conference for 28-July-2005 12:45 PM ET,FCSTEV07/21/05,Banc of America Securities to Webcast Nektar's Corporate Presentation,BW07/11/05,Nektar Therapeutics(NKTR-US) Schedules Q4 2005 Earnings Release for 28-February-2006,FCSTEV07/11/05,Nektar Therapeutics(NKTR-US) Schedules Q3 2005 Earnings Release for 3-November-2005,FCSTEV07/11/05,Nektar Therapeutics(NKTR-US) Schedules Q2 2005 Earnings Release for 4-August-2005,FCSTEV06/20/05,Nektar Therapeutics(NKTR-US) Schedules BIO International Convention for 20-June-2005 2:45 PM ET,FCSTEV06/14/05,Nektar Reports that Pfizer Inc and sanofi-aventis Announce Data Presented at American Diabetes Association Scientific Sessions Support Exubera Efficacy and Safety Profile in Type 1 and Type 2 Diabetes,BW06/06/05,Nektar Therapeutics(NKTR-US) Schedules Pacific Growth Equities Life Sciences Growth Investor Conference for 6-June-2005 12:30 PM ET,FCSTEV06/02/05,Nektar Therapeutics(NKTR-US) Schedules Annual Stockholders Meeting for 2-June-2005 1:00 PM ET,FCSTEV06/02/05,Advisory: Nektar Therapeutics to Webcast its 2005 Annual Meeting of Stockholders,BW05/31/05,Advisory: Pacific Growth Equities to Webcast Nektar's Corporate Presentation,BW05/24/05,Nektar Therapeutics(NKTR-US) Schedules UBS Global Specialty Pharmaceuticals Conference for 24-May-2005 4:00 PM ET,FCSTEV05/18/05,Advisory: UBS Investment Bank to Webcast Nektar's Corporate Presentation,BW05/18/05,Nektar Therapeutics(NKTR-US) Schedules Banc of America Health Care Conference for 18-May-2005 5:00 PM ET,FCSTEV05/12/05,Advisory: Banc of America Securities to Webcast Nektar's Corporate Presentation,BW05/09/05,Nektar Therapeutics(NKTR-US) Schedules Q1 2005 Earnings Call for 9-May-2005 5:00 PM ET,FCSTEV05/09/05,Nektar Announces Appointment of Joseph Krivulka to its Board of Directors,BW05/09/05,Nektar Announces First Quarter 2005 Results,BW05/08/05,Nektar Therapeutics(NKTR-US) Schedules Q1 2005 Earnings Release for 9-May-2005,FCSTEV05/05/05,Advisory: Nektar Sets Date and Conference Call for First Quarter 2005 Results,BW05/04/05,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Securities Health Care Conference for 4-May-2005 10:00 AM ET,FCSTEV04/28/05,Advisory: Deutsche Bank to Webcast Nektar's Corporate Presentation,BW03/31/05,Nektar Therapeutics(NKTR-US) Schedules Lehman Global Health Care Conference for 31-March-2005 11:15 AM ET,FCSTEV03/24/05,Advisory: Lehman Brothers to Webcast Nektar's Corporate Presentation,BW03/16/05,Nektar Therapeutics(NKTR-US) Schedules Cowen Health Care Conference for 16-March-2005 1:30 PM ET,FCSTEV03/10/05,Advisory: SG Cowen to Webcast Nektar's Corporate Presentation,BW03/04/05,"MORNING UPDATE: Man Securities Inc. Issues Alerts for DELL, AW, KSS, NKTR, and TTWO",PRN03/02/05,Nektar Reports that Pfizer and The Sanofi-Aventis Group Seek Approval to Market Exubera in the United States,BW03/01/05,Nektar Therapeutics(NKTR-US) Schedules Q4 2004 Earnings Call for 1-March-2005 5:00 PM ET,FCSTEV03/01/05,Nektar Announces Financial Results for the Year and Fourth Quarter 2004,BW03/01/05,Nektar Therapeutics(NKTR-US) Schedules Wells Fargo Health Care Conference for 1-March-2005 2:00 PM ET,FCSTEV03/01/05,Nektar Therapeutics(NKTR-US) Schedules Suntrust Robinson Humphrey Conference for 1-March-2005 10:20 AM ET,FCSTEV02/28/05,Nektar Therapeutics(NKTR-US) Schedules Q4 2004 Earnings Release for 1-March-2005,FCSTEV02/23/05,Leerink Swann/MEDACorp to Webcast Nektar's Corporate Presentation,BW02/23/05,Advisory: SunTrust Robinson Humphrey to Webcast Nektar's Question and Answer Session,BW02/23/05,Nektar Therapeutics(NKTR-US) Schedules BIO CEO & Investor Conference for 23-February-2005 3:00 PM ET,FCSTEV02/23/05,Advisory: Nektar Sets Date and Conference Call for Year and Fourth Quarter 2004 Results,BW02/17/05,BIO CEO & Investor Conference to Webcast Nektar's Corporate Presentation,BW02/09/05,Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Pharmaceutical Biotechnology and Medical Device Conference for 9-February-2005 3:00 PM ET,FCSTEV02/01/05,"Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Nektar's Corporate Presentation",BW01/25/05,Bayer HealthCare and Nektar Therapeutics Collaborate to Develop Inhaleable Ciprofloxacin Therapy for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients,BW01/24/05,Nektar and Zelos Announce Collaboration to Develop Inhaled Parathyroid Hormone Therapy for Osteoporosis,BW12/17/04,Sixth Product Using Nektar Technology Approved in the U.S.,BW12/07/04,Nektar Therapeutics(NKTR-US) Schedules Informed Investors Biotechnology & Healthcare Forum for 7-December-2004 4:00 PM ET,FCSTEV12/02/04,"MORNING UPDATE: Man Securities issues alerts for RFMD, UTSI, SYMC, NKTR, and CI",PRN12/01/04,"Forum Alert: Nektar Therapeutics Presentation at Informed Investors Biotechnology & Healthcare Stocks Forum at the Crowne Plaza in Foster City on Dec. 7, 2004, 1:00 pm PT",BW12/01/04,Nektar Therapeutics(NKTR-US) Schedules The Lazard Life Sciences Conference for 1-December-2004 8:30 AM ET,FCSTEV12/01/04,"Market Pulse Breaking News Alert for Wednesday, December 1, 2004: PKCY - Park City Group Targets Multi-Billion Dollar Asian Market With High Profile Customers and Patented Language Support Capability!",INW11/22/04,Lazard Life Sciences Conference to Webcast Nektar's Corporate Presentation,BW11/16/04,Nektar Therapeutics(NKTR-US) Schedules SG Cowen Healthcare Conference for 17-November-2004 2:35 AM ET,FCSTEV11/11/04,SG Cowen 5th Annual Global Health Care Conference to Webcast Nektar's Corporate Presentation,BW11/08/04,Nektar Therapeutics(NKTR-US) Schedules CIBC World Markets Health Care Conference for 8-November-2004 4:00 PM ET,FCSTEV11/03/04,Nektar Therapeutics(NKTR-US) Schedules Q3 2004 Earnings Call for 3-November-2004 5:00 PM ET,FCSTEV11/03/04,Nektar Announces Third Quarter 2004 Financial Results,BW11/02/04,Nektar Therapeutics(NKTR-US) Schedules Q3 2004 Earnings Release for 3-November-2004,FCSTEV11/02/04,CIBC World Markets Fifteenth Annual Healthcare Conference to Webcast Nektar Presentation,BW10/20/04,ADVISORY: Nektar Sets Date and Conference Call for Third Quarter 2004 Results,BW10/14/04,Chiron Presents Data on Tobramycin Powder for Inhalation at North American Cystic Fibrosis Conference,BW09/27/04,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Science Conference for 27-September-2004 11:30 AM ET,FCSTEV09/23/04,"Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Drug, Biotech and Medical Devices Conference for 23-September-2004 12:00 PM ET",FCSTEV09/22/04,UBS Global Life Sciences Conference to Webcast Nektar Presentation,BW09/21/04,"Merrill Lynch Global Drug, Biotech and Medical Devices Conference to Webcast Nektar Presentation",BW09/20/04,"Nektar Reports That Pfizer and Eyetech Provide Regulatory Update on Macugen -- pegaptanib sodium injection; EU Filing Accepted, Filing in Canada Completed and Japanese Trial Underway",BW09/09/04,Nektar Therapeutics(NKTR-US) Schedules BioCentury's NewsMakers in the Biotech Industry Investment Conference for 9-September-2004 4:30 PM ET,FCSTEV09/07/04,"Law Offices Of Charles J. Piven, P.A. Announces Class Action Lawsuit Against Nektar Therapeutics -- NKTR",PMZ09/07/04,"Schatz & Nobel, P.C. Announces Class Action Lawsuit Against Nektar Therapeutics",PRN09/07/04,Nektar Reports that New Data on Exubera Showed Sustained Blood Glucose Control and Pulmonary Function in Patients With Type 2 Diabetes,BW09/03/04,"Shareholder Class Action Filed Against Nektar Therapeutics by the Law Firm of Schiffrin & Barroway, LLP",PRN09/02/04,NewsMakers in the Biotech Industry Investment Conference to Webcast Nektar Corporate Presentation,BW08/27/04,Nektar Reports that FDA Advisory Committee Reviews Clinical Data of Eyetech/Pfizer Priority 1 NDA Submission for Macugen,BW08/02/04,Nektar Therapeutics(NKTR-US) Schedules Q2 2004 Earnings Call for 2-August-2004 5:00 PM ET,FCSTEV08/02/04,Nektar Announces Agreement with Pfizer to Use Nektar PEGylation Technology,BW08/02/04,Nektar Announces Second Quarter 2004 Results,BW08/01/04,Nektar Therapeutics(NKTR-US) Schedules Q2 2004 Earnings Release for 2-August-2004,FCSTEV07/29/04,Nektar Therapeutics(NKTR-US) Schedules KBW Community Bank Investor Conference for 29-July-2004 2:15 PM ET,FCSTEV07/22/04,Banc of America Securities 2004 Specialty Pharmaceuticals Conference to Webcast Nektar's Presentation,BW07/19/04,Nektar Sets Date and Conference Call for Second Quarter 2004 Results,BW06/14/04,Nektar Therapeutics to Webcast Its Annual Stockholders Meeting,BW06/08/04,Pacific Growth Equities Life Sciences Growth Conference to Webcast Nektar's Presentation,BW06/07/04,Nektar Reports That New Long-Term Safety and Efficacy Data on EXUBERA --Human Insulin Powder-- Presented at American Diabetes Association Scientific Sessions,BW05/28/04,Friedman Billings Ramsey to Webcast Nektar Presentation at 8th Annual Growth Investor Conference,BW05/20/04,UBS 2004 Global Specialty Pharmaceuticals Conference to Webcast Nektar's Presentation,BW05/14/04,Banc of America Securities 2004 Health Care Conference to Webcast Nektar's Presentation,BW05/07/04,Advisory: SunTrust to Webcast Nektar Corporate Update at Therapeutics Conference,BW05/05/04,Nektar Therapeutics(NKTR-US) Schedules Q1 2004 Earnings Call for 5-May-2004 5:00 PM ET,FCSTEV05/05/04,Nektar Announces Agreements with GlaxoSmithKline and Undisclosed Biotechnology Company,BW05/05/04,Nektar Announces First Quarter 2004 Results,BW04/28/04,Deutsche Bank Securities 2004 Health Care Conference to Webcast Nektar's Presentation,BW04/21/04,ADVISORY: Nektar Sets Date and Conference Call for First Quarter 2004,BW04/13/04,"Nektar Revises Accounting Treatment of Convertible Note Exchange Transactions; No Impact on Cash, Revenue, Operating Expenses, or Operating Loss",BW04/01/04,Nektar Therapeutics Announces Details of Redemption of 6 3/4% Convertible Subordinated Debentures Due October 2006,BW03/30/04,Nektar Therapeutics Announces Completion of Redemption of 3% Convertible Subordinated Notes Due June 2010,BW03/09/04,Nektar Therapeutics Announces Details of Redemption of 3% Convertible Subordinated Notes due June 2010,BW03/08/04,Nektar Therapeutics Announces Intention to Redeem 3% Convertible Subordinated Notes Due June 2010,BW03/08/04,Nektar Therapeutics Announces Common Stock Public Offering,BW03/08/04,"MORNING UPDATE: Man Securities Issues Alerts for AMAT, MCD, MER, NKTR, and PHM",PRN03/04/04,Nektar Reports that Pfizer and Aventis Seek Approval to Market Exubera in Europe,BW03/03/04,SG Cowen 24th Annual Health Care Conference to Webcast Nektar's Corporate Presentation,BW02/27/04,Lehman Brothers Seventh Annual Global Healthcare Conference to Webcast Nektar's Corporate Presentation,BW02/20/04,CORRECTING and REPLACING BIO CEO & Investor Conference to Webcast Nektar's Corporate Presentation,BW02/02/04,Nektar Therapeutics(NKTR-US) Schedules Q4 2003 Earnings Call for 2-February-2004 5:00 PM ET,FCSTEV02/02/04,Nektar Announces Financial Results for the Year and Fourth Quarter 2003,BW02/02/04,Nektar Discloses Collaboration with Roche for CERA,BW01/28/04,"Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Nektar's Corporate Presentation",BW01/21/04,ADVISORY: Nektar Sets Date and Conference Call for Year and Fourth Quarter 2003,BW01/06/04,Nektar Announces Appointment of Susan Wang to its Board of Directors,BW11/06/03,CIBC Annual Healthcare Conference to Webcast Nektar's Corporate Presentation,BW11/05/03,Nektar Therapeutics(NKTR-US) Schedules Q3 2003 Earnings Call for 5-November-2003 5:00 PM ET,FCSTEV11/05/03,Nektar Announces Third Quarter 2003 Results,BW10/27/03,Data Presented by Nektar Therapeutics Show Broad Applications for Its Drug Delivery Technologies,BW10/23/03,Nektar Sets Date and Conference Call for Third Quarter 2003 Financial Results,BW09/16/03,UBS GLOBAL LIFE SCIENCES CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW08/06/03,Nektar Therapeutics(NKTR-US) Schedules Q2 2003 Earnings Call for 6-August-2003 5:00 PM ET,FCSTEV08/06/03,NEKTAR ANNOUNCES SECOND QUARTER 2003 RESULTS,BW07/30/03,NEKTAR ANNOUNCES EXERCISE OF OPTION TO PURCHASE $10 MILLION OF CONVERTIBLE SUBORDINATED NOTES,BW07/22/03,NEKTAR SETS DATE AND CONFERENCE CALL FOR SECOND QUARTER 2003 FINANCIAL RESULTS,BW07/01/03,GENETIC ENGINEERING NEWS REPORTS ADVANCES IN DRUG DELIVERY TECHNOLOGIES,BW06/25/03,NEKTAR THERAPEUTICS ANNOUNCES OFFERING OF CONVERTIBLE SUBORDINATED NOTES,BW06/23/03,NEKTAR THERAPEUTICS ANNOUNCES PROPOSED ISSUANCE OF CONVERTIBLE SUBORDINATED NOTES,BW06/16/03,NEKTAR REPORTS ON PHASE III EXUBERA DATA THAT SHOW BETTER GLYCEMIC CONTROL COMPARED WITH ROSIGLITAZONE IN TYPE 2 DIABETES PATIENTS,BW06/03/03,NEKTAR THERAPEUTICS TO WEBCAST ITS ANNUAL STOCKHOLDERS MEETING,BW05/30/03,UBS WARBURG GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW05/22/03,FRIEDMAN BILLINGS RAMSEY 7TH ANNUAL TECHNOLOGY AND GROWTH INVESTOR CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW05/15/03,CDI Innovantage Wins Contract With Nektar,PRN05/13/03,ENZON PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS; TOTAL REVENUES INCREASE BY 118% AND PHASE II CLINICAL TRIALS INITIATED FOR PROTHECAN IN GASTRIC CANCER,BW04/30/03,DEUTSCHE BANK 28TH ANNUAL HEALTH CARE CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW04/22/03,NETKAR ANNOUNCES FIRST QUARTER 2003 RESULTS,BW04/15/03,NEKTAR SETS DATE AND CONFERENCE CALL FOR FIRST QUARTER 2003 FINANCIAL RESULTS,BW03/27/03,FIFTH PRODUCT USING NEKTAR TECHNOLOGY APPROVED IN U.S.; FDA APPROVES PHARMACIA CORPORATION'S SOMAVERT FOR THE TREATMENT OF ACROMEGALY,BW03/14/03,SG COWEN ANNUAL HEALTHCARE CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW03/03/03,NEKTAR CREATES NEW EXECUTIVE POSITION AND ADDS TO MANAGEMENT TEAM TO LEAD COMPANY TO FURTHER GROWTH AND TOWARD PROFITABILITY,BW02/28/03,LEHMAN BROTHERS TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW02/19/03,BIO CEO & INVESTOR CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW02/18/03,"ENZON FILES FORM 10-Q FOR QUARTER ENDED DECEMBER 31, 2002; REFLECTS NON-CASH REVISION TO SECOND QUARTER FINANCIAL RESULTS",BW01/31/03,"MERRILL LYNCH GLOBAL PHARMACEUTICAL, BIOTECHNOLOGY AND MEDICAL DEVICE CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION",BW01/28/03,NEKTAR ANNOUNCES FOURTH QUARTER AND YEAR ENDED 2002 FINANCIAL RESULTS,BW01/23/03,"NEKTAR THERAPEUTICS AND  THE STRAUMANN GROUP ANNOUNCE LICENSE, MANUFACTURING AND SUPPLY  AGREEMENT FOR DENTAL APPLICATIONS",BW01/21/03,ADVISORY/NEKTAR SETS DATE AND CONFERENCE CALL FOR FOURTH QUARTER AND YEAR ENDED 2002 FINANCIAL RESULTS,BW01/15/03,INHALE BECOMES NEKTAR THERAPEUTICS REFLECTING BROADENED CAPABILITIES AND EXPANDED APPROACH TO DRUG DELIVERY,BW